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ABSTRACT 
 
Cancer Initiating cells are a small population of cancer cells capable of tumor initiation and 
growth. Characteristic of these cells are the expression of “stem-like” markers and the common 
alteration of the Wnt/β-catenin and Notch pathways. In my thesis, I characterized Colon Cancer 
Initiating Cells (CCICs) by FACS analysis from HT-29 colon cancer cell line. I then performed in 
vitro colonospheres-forming assay and RNA-Seq, to interrogate the genome-wide signature 
involving CCICs. My results show that members of Wnt/β-catenin pathway are elevated in CCICs 
and colonospheres, when compared to a more differentiated population. Moreover, genes 
directing the differentiation were silenced in CCICs and colonospheres. These results demonstrate 
the self-renewal and proliferation capacity of the isolated CCICs population, and that this 
subpopulation resembles a strong Wnt-signaling pathway signature. Additionally, several 
lncRNAs are dys-regulated in CCICs, and my findings identify LUST/RBM5-AS1 as a lncRNA 
transcript strongly elevated during colonospheres formation. The expression of LUST and stem-
like markers CD24 and CD44, and expression of Wnt-signaling corresponds with cells that can 
survive and grow in serum-free media. Loss of LUST impairs Wnt-signaling at mRNA and protein 
levels, while LUST overexpression provides enhanced and synergistic signaling mediated through 
Wnt and β-catenin at the mRNA and protein levels. Nuclear/Cytoplasmic RNA fractionation and 
RNA-FISH show that LUST essentially is a nuclear transcript. RNA immuno-precipitation and 
UV cross-linking immuno-precipitation assays show that LUST RNA binds to β-catenin. Finally, 
LUST overexpression enhances colonospheres formation more rapidly. Collectively, my findings 
reveal that the lncRNA LUST regulates Wnt pathway in CCICs through a coordinated physical 
interaction with β-catenin, acting through transcriptional regulation to promote colon cancer 
initiating cells maintenance.  
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CHAPTER I: INTRODUCTION 
 
 
1. Colorectal Cancer 
1.1 Colorectal cancer and Intestinal Stem Cells 
 
 
Colorectal cancer is the third most common cancer and the third cause of cancer death in the 
United States. In 2014, the estimated new cases for colon cancer and rectal cancer were ~90,000 
and 40,000 respectively, with the combined number of deaths annually estimated at  ~50,000 
(American Cancer Society. Colorectal Cancer Fact and Figures 2014-16). The colon, or large 
intestine, is anatomically composed of four distinct cellular layers, and the inner luminal layer 
contains epithelial cells folded into finger-like invaginations, embedded in the sub-mucosal tissue 
to form the crypt of Lieberkhun 
1
, functional unit of this organ. In each crypt are present around 
2,000 cells, included three mainly differentiated cell lineages: enterocytes, goblet cells and 
endocrine cells. The differentiated cell lineages reside within the top-third of the crypt 
2,3
. These 
epithelial cells are subjected to a continuous turnover, given that they shed into the lumen once 
they become senescent 
4,5
.  Understanding the mechanisms that regulates intestinal stem cells 
(ISCs) is radical to elucidate the biology of their malignant counterpart. In fact, the ISCs, 
characterized by self-renewal and multipotent undifferentiated cells, are responsible for the rapid 
turnover of intestinal epithelium (5 days). Their cell division is mainly asymmetrical: among the 
two daughter cells generated, one daughter cell is identical to the original cell, while the second 
forms a progenitor cells with the capacity to differentiate. Progenitor cells migrate to the top of 
the crypt and reproduce the fully differentiated cell environment 
6-8
. The intestinal 
microenvironment (niche) consists of several components, cellular and extracellular, that provide 
the best conditions for stem cells maintenance through secretion of growth factors, cytokines and 
direct interactions 
6,9
.  Intestinal subepithelial myofibroblasts (ISEMFs) are considered key 
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regulators of stem cells self-renewal and differentiation and are extremely involved in the 
interactions between epithelial and mesenchymal cells 
3
. These interactions are able to keep the 
right balance between proliferation and differentiation through the regulation of several pathways 
as Wingless/Int (Wnt), Sonic hedgehog (Shh) and Notch.   
 
The cellular process that leads from a normal colonic epithelium to invasive colorectal cancer 
(CRC) is a multistep oncogenic process, which goes from normal to dysplastic epithelium, 
formation of adenomatous polyps and, in the later stages, to invasive CRC. Each step in the tumor 
progression is marked by evolution of prominent genetic alteration. Faeron et al. proposed that 
mutations in adenomatous polyposis coli gene (APC) arise in the early stages of transformation, 
leading to hyperproliferation and formation of class I adenoma; class II andenoma are generally 
induced by K-Ras mutations; while loss of ‘Deleted in Colorectal Cancer’-DCC- is responsible 
for class III adenoma; and ultimately, p53 mutations are responsible for invasive cancer 
10
. 
Significant findings have been noted in the frequency of known genetic mutations, like the ones 
just mentioned, that influence stem cell dynamics in tumor initiation 
11
. Furthermore, the extent of 
stem cell clonal advantage, which constantly increases during tumor progression, is influenced by 
oncogenic and environmental factors therefore playing an important role in CRC initiation.  
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1.2 Cancer Initiating Cells (also known as Cancer Stem Cells, CSCs) 
 
Our knowledge of how Cancer Initiating Cells (CICs) promote asymmetrical tumor growth and 
maintain stem like characteristics is still poorly understood. During the past few decades many 
new findings have been recognized in understanding the patterns and markers of cells growth 
within human tumors. However, more detailed investigation is necessary to understand the stem-
like character of these cells as initiators of tumor growth and metastasis. A central concept of 
CICs is that tumors express extensive heterogeneity of cells, with a select few endowed with the 
capacity to self renew and to maintain this specific function over the evolution of tumor growth 
and metastasis. It has been carefully documented that cells present in the bulk of a tumor consist 
of the spectrum of rapidly proliferating cells to postmitotic and differentiated cells. Moreover, the 
growth of tumors is based on the presence of a small subpopulation of cells with the capability of 
self-renewal and asymmetrical growth, hence evidence of CICs in CRC 
12
. 
 
The history of CICs begun with a finding by Furth and Kahn, on 1937 
13
, when they demonstrated 
that a single cells from a mouse tumor, injected into another recipient mouse, could variably 
initiate a new tumor growth, suggesting the existence of cell-type heterogeneity that defines a 
small population of cells with a capacity of initiating a new malignancy. Later in the mid-1900s, 
new approaches became more widely available to identify proliferating cells, as radiolabeling and 
autoradiography became more prominent 
14
. In 1971, using radiolabeled phosphorus on a 
squamous cell carcinoma, Pierce et al. demonstrated that that most of the undifferentiated areas 
showed early and rapid labeling of DNA, and, during later stages of cell growth, the well-
differentiated areas effectively expressed the DNA radioactive label, demonstrating that the 
differentiated cells were derived from undifferentiated “stem-like” population of cells. 
Furthermore, well-differentiated cell population, injected into compatible hosts, was unable to 
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form tumors 
15
. Pierce and colleagues therefore, hypothesized the theory of cancer initiation as: “a 
concept of neoplasm, based upon developmental and oncological principles, states that 
carcinomas are caricatures of tissue renewal, in that they are composed of a mixture of malignant 
stem cells, which have marked capacity for proliferation and limited capacity for differentiation 
under normal homeostatic conditions, and of the differentiated possibly benign, progeny of these 
malignant cells”.  
 
At the same time the concept of clonal evolution came out from studies performed by Nowell, 
16
, 
who proposed that “most neoplasms arise from a single cell of origin, and tumor progression 
results from acquired genetic variability within the original clone allowing sequential selection, 
leading to more aggressive subclones. Tumor cell populations are apparently more genetically 
unstable than normal cells, leading to the greater capacity for cellular heterogeneity.  The 
acquired genetic instability and associated selection process, most readily recognized 
cytogenetically, results in advanced human malignancies being unique in their karyotype and 
biological profiles in tumor growth. Therefore, each individual’s malignant disease may require 
personalized approaches to molecular based therapies, and even this may be challenged by the 
evolution and emergence of a genetically variant subclones resistant to the chemoterapeutic 
treatment” 16.  About twenty years later, John Dick and colleagues revives CSC theory by 
xenografting human acute myeloid leukemia (AML), using CD34
+
CD38
-
 fractions into 
immunocompromised host mice. In this study the frequency of the initiating cell was found on 
order of one per million tumor cells, leading to the identification of CIC in AML with unique 
stem-like character 
17,18
.  In 2003 Clark and his colleagues 
19
 applied this system for the first time 
to a solid breast cancer tumor, and isolated a cell fraction CD44+ CD24-/low that was the only 
one able to generate new tumors in immunodeficient mice, as well as the nontumorigenic cells 
present in the initial tumor. Similar studies on brain 
20
 and colon c 
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ancer 
21-23
 were published there after. Therefore, what makes cells CICs is the ability of (1) being 
the source of all of the malignant cells present in a tumor; (2) resistance to chemotherapeutic 
agents that makes them responsible for recurrence; and (3) giving rise to metastases.  
 
The combination of several markers can be used to identify and enrich the CICs population in 
different kind of tumors (Table 1.1). Indeed, based on the heterogeneity of several markers, 
specific subpopulations of cells can be sorted from primary tumors or cell lines and injected in 
immunodeficient mice by subsequent serial passages. The capacity of this subpopulation of cells 
for making new tumors is interpreted as evidence of CICs in the primary tumor.  
 
 
Table 1.1: Cell surface phenotypes of Cancer Stem Cells in different tumor types 
24
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1.3 Colon Cancer Initiating Cells, CCICs (also known as Colon Cancer Stem Cells) 
 
 CSCs are identified a small subpopulation of cells endowed with the ability of self-renewal, the 
capacity of giving rise to asymmetrical growth of the parental tumor, possessing intrinsic 
resistance to chemotherapeutic drugs and elevated insensitivity to radiation, and can form new 
tumors, metastasize and relapse after tumor regression 
25
. The first description of colon cancer 
stem cells (CCSCs) was provided by Dick and De Maria independently 
22,23
. Dick and colleagues 
demonstrated that by implanting serial dilutions of human colon cancer cells into 
immunodeficient mice, only a small population equal to 1/5.7 x 10
4
 of total cells, could induce 
tumor growth. Using the antibody directed against CD133 antigen (Prominin), they were able to 
sort two different subpopulations and noticed that the CD133- subpopulation was also able to 
form tumors but the tumor formation was taking more time compared to the one originated from 
the CD133+ subpopulation. Dick and colleagues then concluded that CD133- cells were 
malignant cells derived from asymmetric division of CD133+ cells, and that not every CD133+ 
cell was able to give rise to tumor formation. Limiting dilution assays showed that only 1 of 262 
CD133+ colon cancer cells could induce tumor formation 
22
.  Ricci-Vitiani group also identified 
CD133 as a potential CCSCs marker, but they noticed also that the same subpopulation of cells 
was cytokeratin (CK) 20 negative. In fact, CK20 is a colonic epithelial differentiation marker, so 
not supposed to be expressed on stem cells.  Through in vitro colonospheres formation assay, they 
showed that CD133+ cells could be isolated by plating single cells from colon cancer tissues in 
serum free media, supplemented with epidermal growth factor and basic fibroblast growth factor.  
In these conditions, CD133+ cells could form spheres-like aggregates, proliferate at an 
exponential rate and increase their aggressiveness through many passages in vivo. Also, after 
inducing differentiation by adding serum, they noticed that the expression of CD133 was 
decreased, along with the gaining of CK20 expression 
23
.  More evidence by Todaro et al, showed 
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that CD133+ cells are able to generate colonies organized as a crypt-like structure, when cultured 
on Matrigel, under differentiation conditions. Furthermore, they demonstrated that this 
subpopulation of cells was strongly resistant to apoptosis by generating Interelukin-4 (IL-4) 
26
.   
 
The cell surface protein CD133 is a five-transmembrane glycoprotein identified as the first 
CCSCs marker 
22,23,26,27
. Although several interesting findings were noted with the CD133 cell 
surface marker, its use as a source of cancer initiating cell populations remains controversial. 
Many in the field, consider that: (i) cell surface expression of CD133 is not solely restricted to the 
stem compartment but has been found to be expressed throughout the normal gastro-intestinal 
tract 
28
 and (ii): CD133+ as well as CD133- are able to form tumors 
29
. This was the first attempt 
to identify the actual CSCs, but during the years, several additional cell surface antigens have 
been associated with the cancer stem cell phenotype, i.e.: CD44 
21,30,31
 CD166 
21
, CD24, CD29 
27
, 
and Lrg-5 
32
. In a hallmark study by Young et al it has been further demonstrated that isolated 
CD24+/CD44+ subpopulations from different colon cancer cell lines, were capable to self-renew 
and to reestablish all the CD24/CD44 subpopulations in vitro and in vivo 
33
.  
 
In the attempt of finding more specific markers to characterize CCSCs, the cell surface antigens 
CD24 and CD44 were used in combination with CD133 
22,23,27,34
. CD24 is a small glycoprotein, 
consisting of 27 amino acids, and is attached to the cell membrane through a phosphatidylinositol 
anchor 
35
. It is a heavily glycosylated protein, expressed in a wide variety of cancer cells and is 
directly involved in cell-cell and cell-matrix interactions 
36-38
. CD24 was first discovered in mice 
as a heat-stable antigen, expressed on hematopoietic 
39
 and neuronal cells 
40
.  At the functional 
level, CD24 is considered an alternative ligand for P-selectin, the adhesion receptor present on 
platelets and endothelial cells 
41
, and their interaction facilitate the passage of cancer cells through 
the blood stream during formation of metastatic tumors. Therefore is considered to increase 
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proliferation rate and adhesion of tumor cells to fibronectin, laminin and collagen 
42
.  Recent 
studies found that CD24 can be co-expressed with CD29, CD31 and CD44 in various cancers and 
with different functions 
27
. For example, in pancreatic cancer, the expression of CD24 on both, 
the surface membrane and the intracellular environment, inhibits the cell invasion and metastasis 
43
, while other studies showed that in lung cancer CD24 is involved in tumor progression 
36
, and 
in the formation of metastatic tumors in other solid tumor types 
44
. The expression of the cell 
surface antigens CD24 in combination with CD44 in colorectal cancer stem cells has been shown 
in several studies 
33,45
.  
 
The cell surface antigen CD44 belongs to the family of cell adhesion molecules (CAMs). CD44 is 
a transmembrane glycoprotein and together with selectins, integrins and cadherins controls the 
interactions between cells or between cells and extracellular matrix, therefore extremely 
important to sustain the tissue integrity 
46
.  There are several protein isoforms of CD44, all 
alternative splicing forms deriving from a single gene present on chromosome 11 in humans, but 
the smallest and ubiquitously expressed form is the CD44s (Reviewed in 
47
). At the functional 
level, CD44 plays an important role in promoting migration, proliferation, motility, growth, 
migration, survival, angiogenesis and differentiation 
30,48
.  It has been shown that CD44 
interaction with osteopontin regulates its cellular function and leads to tumor progression 
49
, it 
also interacts with P- or L-selectin, and as for CD24, it helps the cancer cells to spread through 
the blood stream 
50
.  Interestingly, CD44 expression is regulated by Wnt signaling; weather or not 
the regulation is direct or indirect remains unclear 
51
, although recent studies showed that CD44 
physically associates with LRP6 upon Wnt treatment and modulates LRP6 membrane 
localization, acting as a positive regulator of the Wnt receptor complex 
52
.   
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1.4 Wnt/β-catenin signaling  
 
 
One of the common dys-regulated pathways in CRC is the Wnt/β-catenin signaling. The wnt1 
gene, initially termed Int-1, is a proto-oncogene encoding a cysteine-rich secreted protein, and 
was first identified in 1982 
53
. A few years later, Nusslein-volhard and Wieschaus discovered the 
fly wingless (wg) gene, which controls segment polarity during larval development and is a 
homolog of wnt1 
54. In early 1990’s, epistasis experiments in Drosophila melanogaster 55-57 and 
developmental studies in Xenopus 
58
 demonstrated that the entire Wnt pathway was evolutionary 
and highly conserved and referred to it as the canonical Wnt signaling cascade. Major discoveries 
were noted in late 1990’s with the identification of TCF/LEF transcription factors 59,60 and β-
catenin 
61
 as Wnt nuclear effectors, Frizzled as Wnt receptors 
62
 and LRPs/Arrows as co-receptors 
63
.  The human genome contains nineteen confirmed Wnt genes, falling into twelve conserved Wnt 
gene subfamilies. Of note, most mammalian genomes harbor Wnt genes 
64
 while is interesting 
noticing how single-cell organism do not have Wnt genes, suggesting that this pathway is 
extremely important in evolution 
65
.  
 
The Wnt family genes are expressed as proteins of approximately 40kDa size, contain many 
cysteines 
66
 and are frequently lipid-modified 
67
 for the induction of signaling and Wnt secretion 
68,69
. Wnt signaling appears to occur mostly between cells in proximity of each other, like the 
adult stem cell niche 
70,71
, making the Wnts signals acting over a short-range 
72
 Once the Wnt 
proteins reach the surface of the target cells, they bind an heterodimeric complex formed by a 
seven-transmembrane (7TM) receptor, named Frizzled (Fz), that contains a large extracellular N-
terminal cystein-rich domain (CRD) 
62
, that acts as a platform for Wnt ligand binding 
73,74
, and a 
single-pass transmembrane molecule called LRP5 and-6 in vertebrate 
75,76
 and Arrow gene in 
Drosophila 
63
. The altered conformation of the receptor induced by the ligand, is followed by the 
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Axin binding to the cytoplasmic tail of LRP6 
77
, which is phosphorylated by two kinases, 
glycogen synthase kinase 3-beta (GSK3-β) and casein kinase 1-gamma (CK1-γ). GSK3β is also 
responsible for the serine phosphorylation in PPPSP motif present in β-catenin, Axin, and APC 78.  
At the same time, the cytoplasmic domain of Fz interacts with Dishevelled (Dsh) 
79
 facilitating 
Axin and LRP6 tail interaction through a common DIX domain 
80,81
.  The Axin protein acts as 
scaffold for the assembling of the “destruction complex” consisting of β-catenin, the tumor 
suppressor APC, and the kinases CDK1-α/γ and GSK3-α/β. APC is able to bind at the same time 
Axin and β-catenin trough three axin-binding motifs that are interspersed between a series of 15-
20 aa repeats that bind β-catenin, and it has been shown that is extremely important for the 
destruction complex function in colon cancer, although its specific molecular function remains 
unclear 
82
.  In an inactive state CK1 and GSK3 sequentially phosphorylate the β-catenin that is 
bound to Axin, at a series of N-terminal Ser/Thr residues. The phosphorylated β-catenin is then 
recognized by the specific protein b-TrCP belonging to the E3 ubiquitin ligase complex and 
targeted for destruction by the proteasome 
83
. β-catenin degradation, therefore, prevents the Wnt 
target genes activation. 
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In an active state, the complex instead becomes saturated by phosphorylated β-catenin and new 
protein is synthetized ad accumulated in the cytoplasm, ready for nuclear migration 
84
. (Fig.1.1) 
 
 
 
Figure 1.1: Reproduction of Wnt pathway in inactive and active state 
In the absence of Wnt ligand (left), the destruction complex resides in the cytoplasm, and induces binding, 
phosphorylation, and ubiquitinilation of β-catenin by β-TrCP. The proteasome recycles the complex by 
degrading β-catenin. In the presence of Wnt ligand (right panel), the intact complex associates with 
phosphorylated LRP. Once is bound to LRP, the destruction complex stills captures and phosphorylates β-
catenin, but ubiquitination by β-TrCP is blocked. Newly synthesized β-catenin accumulates. 72 
 
 
Once entering the nucleus, β-catenin engages DNA-bound TCF/LEF transcription factor 59,60. 
When the system is turned off, TCF interacts with a member of the Groucho (also referred to as 
the Transducin-like enhancer) family of transcriptional repressors, and the gene transcription is 
repressed. In the active state, TCF/LEF and β-catenin associate and TCF/LEF is transiently 
converted in a transcriptional activator of Wnt-mediated target genes 
85,86
 as MYC 
87
 and CCND1 
88
, involved in cell proliferation. (Fig. 2.1) 
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Figure 2.1: Nuclear Wnt-signaling 
In absence of Wnt ligand, TCF and the transcriptional corepressor Groucho, occupy and repress Wnt-target 
genes. When Wnt signal is present, β-catenin replaces Groucho from TCF and recruits other transcriptional 
activators and histone modifiers such as Brg1, CBP and other.  
72
 
  
 
Although the mechanism of how β-catenin shuttles between the cytoplasm and the nucleus 
remains to be clearly resolved, it’s been shown that the fold change rather than absolute levels are 
critical, suggesting that low levels of this protein is capable of inducing important transcriptional 
changes 
89
.  
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2. Long Noncoding RNAs 
 
From a pure molecular perspective, cancer is a disease involving both, genetic and epigenetic 
mechanisms, due to aberrant function and expression of genes regulating tumor suppression and 
oncogenesis and at the same time, hundreds to thousands of lncRNAs have been involved in 
cancer and oncogenesis. In the following paragraphs, I provide a comprehensive introduction 
from existing literature of lncRNAs and their emerging roles in cancer and cancer initiating cells 
related to the findings in the thesis. 
 
2.1 Biogenesis and function of lncRNAs 
 
New techniques for genome sequencing have shown that the majority of the eukaryotic genome is 
pervasively transcribed, but less than 2% is ultimately translated into proteins 
90-92
, suggesting 
that non-coding RNAs impose another layer of regulation functioning throughout the human 
genome.  Non-coding RNAs (ncRNAs) can be distinguished in different categories according to 
their length, expression and function. The small ncRNAs class includes microRNAs (miRNAs), 
small interfering RNAs (siRNAs), and Piwi-associated RNAs (piRNAs), all of them shorter that 
200 nucleotides 
93
; RNA transcripts with a length above 200 nucleotides, often polyadenylated 
and devoid of evident open reading frames (ORFs), are defined as long noncoding RNAs 
(lncRNAs) 
94-96
.  
 
According to the accumulated datasets from the ENCODE Project Consortium as of the year 
2012, there are approximately 9640 lncRNA loci in the human genome that have been recognized 
95,97
, and as sequencing technology rapidly emerges from single cell approaches to increases in 
the depth of coverage, lncRNA populations are rapidly being identified. Several studies showed 
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that they are involved in the regulation of chromatin organization, transcriptional and post-
trascriptional levels 
98
, and in tumorigenesis 
99
.  
 
Based on LNCipedia 2.0, the lncRNAs database (http://lncipedia.org/db/search) there are 32,183 
human annotated lncRNAs, and among them only very few have been validated either 
functionally or biologically 
100
. The transcription of lncRNAs can arise from intergenic or 
intragenic regions; the lncRNAs arising from intergenic regions are called large intergenic 
ncRNAs (lincRNAs), and are typically located 5kb away from protein coding genes 
101
. 
LncRNAs arising from intragenic regions can be further classified as in antisense, overlapping, 
intronic, with bidirectional orientations relative to protein-coding genes or gene regulatory 
regions, such as UTRs, promoters and enhancers (Reviewed in 
102
). Like their protein-coding 
gene counterparts, ncRNA transcript expression can be controlled by transcriptional and 
epigenetic factors, in particular multiple transcription factors (TFs) such as Nanog, Oct4, 
NFkappaB, Sox2 and tumor protein 53 (TP53) are found to transactivate their expression 
101,103
. 
Again, like their protein-coding gene counterparts, lncRNAs are subjected to post-transcriptional 
processing and modification 
95,97
 such as 5’ capping, polyadenylation, alternative splicing or RNA 
editing 
104
. At the structural level, given their length, lncRNAs maintain complex secondary and 
tertiary structure, favoring the duplexing with DNA and other RNA molecules as well as through 
interactions with numerous RNA binding proteins, to impose biochemical and biological 
activities. Therefore, lncRNAs can function as activators, decoys, guides, or scaffolds for 
transcription factors and histone modifiers 
105
 (Fig. 3.1) as described below:  
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1. Long non-coding RNAs can function as transcriptional activators by directly interacting 
with transcriptional factors, favoring an allosteric change to promote trans-activation of 
target gene transcription (Fig. 3.1, top left). 
2. Long non-coding RNAs can silence transcription factor function by sequestering 
transcription factors away from chromatin (Fig. 3.1, top right). 
3. Long non-coding RNAs can function as transcriptional guides by recruiting chromatin-
modifying enzymes to target genes, either in cis or in trans and altering gene expression 
(Fig. 3.1, bottom left). 
4. Long non-coding RNAs can function as scaffolds (platforms) for chromatin modification 
complex that form ribonucleoprotein complexes (Fig. 3.1, bottom right). 
 
 
Figure 3.1: Functions of lncRNAs 
Top left) transcriptional activators; top right) transcriptional repressor; bottom left) transcriptional 
guide; bottom right) scaffold for chromatin modification complex. (Modified from 
106
) 
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Examples of lncRNAs involved in some of these complicated interactions are reported in 
Table 2.1.  
 
 
Table 2.1: Example of different kinds of lncRNAs interactions (Modified from 
106
)
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2.2 lncRNAs in cancer 
 
2.2.1 Genetic and epigenetic changes deregulating lncRNAs 
 
Previous known variation in DNA copy number (or copy number variation) commonly occur 
in non-coding regions of the human genome, and had remained inexplicable. Because of 
recent advancements in genome–wide sequencing technologies, many of these same regions 
were revealed as transcribed elements and can involve microRNAs, SINE, LINE transcripts 
and lncRNAs like LOC285194 which has been demonstrated to act as a tumor suppressor. 
Furthermore, genetic deletion of the LOC285194 locus is associated with poor survival of 
patients affected by osteosarcoma 
107
. Loss of heterozygosity  (LOH) of the maternal allele of 
KCNQ1OT1 is also associated with cancer, as well as gene deletion of PTENP (PTEN-
Pseudogene) in melanoma patients 
108
.  
A study conducted by Akrami et al. identified that an intergenic lncRNA on chromosome 1, 
OVAL, shows narrow focal genomic amplification in a defined subset of ovarian cancer, 
providing evidence of the strong effect of lncRNAs in cancer development 
109
. The emerging 
role of the genetic changes affecting the lncRNAs expression has been shown in several types 
of cancer. For example, the effect of the single nucleotide polymorphisms (SNPs) rs1456315 
and rs7463708 is associated with cancer susceptibility and expression of the oncogenic 
lncRNA PRNCR1 in prostate cancer 
110
.   
Several additional lncRNAs are localized within the imprinted loci, playing an important role 
in the imprinted loci formation and maintenance 
111
, as their localization make loci being 
susceptible to epigenetic activation or inactivation. Few examples are represented by H19 that 
is de-repressed by Mineral dust-induced gene (Mdig). The Mdig gene is responsible for the 
down-regulation of H3K9me3 and heterochromatin in the H19 loci, inducing the increase of 
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the oncogenic H19 
112
. Defect of imprinting correlating an increase of lncRNAs expression are 
also reflected by KCNQ1OT1 in multiple cancers 
113-116
.  
 
2.2.2 LncRNAs in cancer initiation, progression and metastasis 
 
Tumor formation is the result of the interaction between the cancer cell and the 
microenvironment. Dependent on these intricate interactions, cancer cells are able to acquire 
the ability for sustaining proliferative signaling, enabling replicative immortality, inducing 
angiogenesis, evading growth suppression, resisting cell death, activating invasion and even 
acquire drug resistance 
117
. The three stages of cancer are characterized by initiation, growth 
and metastasis, and a large number of protein coding genes have been demonstrated to be 
involved in these processes. Despite this knowledge, how these genes are deregulated is not 
fully understood. Little is known about noncoding genes and their role in cancer, but emerging 
evidence show that noncoding RNAs play a role in cancer development.  
 
Expanding findings, based on genome-wide sequence information and animal modeling using 
selected cell populations from tumors, suggest that specific cells acquire traits similar to 
embryonic stem cells for asymmetrical growth and cellular diversification. Through this 
evidence, key genes and proteins governing the embryonic and adult stem cell multipotency 
are identical or similar in cancer stem cells 
118
. Regarding cancer initiation, it has been 
demonstrated from Trimarchi et al., that there is a set of T cell acute lymphoblastic leukemia 
(T-ALL) associated lncRNAs directly regulated by the Notch/Rpbjk activator complex. In 
particular, the lncRNA LUNAR1, is required for T-ALL growth in vivo and in vitro, given to 
its potential of inducing IGFR1 mRNA and therefore sustaining IGF1 signaling 
119
 
.  
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The Polycomb repressive complex-1 (PRC1) and -2 (PRC2) promote stem cell self-renewal 
and inhibit differentiation, playing a role in tumor progression and development. PRC1 core 
complex includes BMI1, mPh1/2, Pc/Chromobox (CBX) and the ubiquitin E3 ligase Ring A/B 
proteins, while EED, SUZ12 and EZH 1/2 are mainly members of PRC2 complex 
120
.  A 
growing body of evidence shows that members of the Polycomb repressive complex interact 
with lncRNAs 
121
. The lncRNA ANRIL physically interacts with CBX7, a member of the 
PRC1 complex, where this interaction forms heterochromatin surrounding the INK4b-ARF-
INK4a locus, leading to its repression. This mechanism facilitates the bypassing of 
senescence, endowing stemness of PC3 prostate cancer cells for sel-renewal 
122,123
.  Another 
lncRNA involved in PRC interaction is the oncogenic HOTAIR, responsible for the 
relocalization of the PRC2 complex towards a metastasis expression profile 
124
. Other studies 
include lncRNAs lined with cell cycle pluripotency regulators, such as p53, Pou5f1/Oct4, 
NFkappaB and Nanog 
101,125
, essential for eradication or establishment of cancer stemness 
respectively 
126
.  
 
The process that leads to the formation of a visible tumor mass, arising from a few cancer 
initiating cells, is defined as cancer growth referring to tumor cell proliferation, resistance to 
death (apoptosis) and angiogenesis. Several lncRNAs have been identified as contributor to 
cancer cell proliferation, and an example is given from PCAT-1, which can promote prostate 
cancer cell proliferation 
127
 as well as PCGEM1 
128-130
. The lncRNA H19 has been 
characterized for its ability to promote the anchorage-independent growth of primary breast 
and lung carcinoma cell lines 
131,132
. On the other hand, the growth arrest-specific 5 (Gas5) 
lncRNA, associated with the ability of inducing cell growth arrest, was found down-regulated 
in breast cancer 
133
.  
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Angiogenesis occurs upon hypoxia and becomes another acquired characteristic of the tumor. 
Several studies identified lncRNAs involved in angiogenesis, and in particular, genetic 
deletions or pharmacological inhibition of MALAT1 reduce vascular growth in vivo, as shown 
from Michalik et al 134. Furthermore, elevated MALAT1 transcript expression was found in 
colon, lung and liver cancer 
135-137
, suggesting a specific role in cancer progression by 
promoting angiogenesis. Other studies suggest that MEG3 may inhibit angiogenesis in vivo 
138
 
and LOC285194 could inhibit the VEGFR1 
107
. Following angiogenesis, cells adopt a 
migratory mesenchymal character to facilitate colonization in different tissue through a 
peripheral blood vessel, thereby forming metastasis. Some lncRNAs have also been directly 
lined to the metastatic process. For instance, HOTAIR overexpression leads to breast cancer 
metastasis as seen in an in vivo assay, by altering the transcription profile and favoring de-
differentiation of the subcellular populations into mesenchymal–like character followed by 
metastasis. HOTAIR lncRNA expression is increased in 25% of breast cancer patients, whose 
tumor staging correspond with the appearance of distant metastatic tumors 
124
. High 
expression levels of this lncRNA, has also been observed in advanced stages of colon, liver 
and pancreatic cancer 
139-142
. The lncRNA-activated by TGF-b (lncRNA-ATB) was found to be 
upregulated in hepatocellular carcinoma metastases and has been associated with poor 
prognosis. Expression of lncRNA-ATB correspond with ZEB1 and ZEB2 expression by 
competitively binding the mir-200 family, thereby inducing EMT and invasion. In addition, 
the same lncRNA promotes organ colonization of disseminated tumor cells by binding IL-11 
mRNA and triggering STAT3 signaling 
143
.  
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2.2.3 LncRNAs as diagnosis markers and therapeutic targets 
 
 
Analogous to the detection of miRNAs, lncRNAs can be detected from various body fluids by 
RT-PCR and suggest their putative use as diagnostic and prognostic indicators of disease 
outcomes. Although these studies remain underdeveloped at the current time, emerging 
technologies show how is it feasible to detect the lncRNA PCA3 in prostate cancer patient 
urine samples, or the lncRNA transcript FR0348383 in post digital rectal examination (DRE) 
urine 
144
, and the lncRNA HULC in HCC patient blood 
145-147
 as transcript signatures of 
malignant disease. A recent study from Tong et al. showed that the lncRNA POU3F3 can be 
detected from esophageal squamous cell carcinoma (ESCC) patient plasma samples, as a 
potential biomarker for early screening of ESCC 
148
.  
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2.3 The lncRNA LUST (RBM5-AS1) 
 
 
In 2009, Rintala-Maki et al identified and characterized a novel antisense non-coding RNA 
from the RNA binding motive 5 (RBM5) locus 
149
. The RBM5/LUCA-15/H37 gene is 
transcribed in both the sense and antisense orientations 
150,151
 and encodes products that are 
able to differentially modulate apoptosis, depending on the transcript splice variant that arises. 
Alternative splicing of RBM5 pre-mRNA produces at least five variants: RBM5, RBM5Δ6, 
RBM5+5+6, RBM5+6 and RBM5+5+6t/Clone 26 
152
. In overexpression studies from various 
cell line, the full length RBM5 transcript sensitizes cells to apoptotic signal and varies with 
cell type 
153-157
. The alternative splice variant RBM5Δ6, lacking exon 6, inhibits apoptosis and 
increase cell growth when overexpressed in the CEM-C7 leukemia cell line 
155
; RBM5+6, 
including intron 6, and RBM5+5+6, including both intron 5 and 6, contain a premature stop 
codon, thus targeting the transcripts as candidates for nonsense-mediated decay (NMD). 
RBM5+5+6t/Clone 26 (GenBank accession no. AF107493) is a truncated form of RBM5+5+6 
and is pro-apoptotic/cytotoxic; the small cDNA Je2 (326 bp) was originally identified by 
Sutherland et al. as an antisense to RBM5+5+6t/Clone 26 and they demonstrated that is able to 
confer dramatic apoptosis resistance to cells treated with normally lethal levels of agonistic 
anti-Fas antibody 
150
. Several years later, the same group discovered that Je2 was only a 
fragment of a larger transcript, and in particular of a transcript of ~1.4kb length termed LUST 
(Luca-15-specific transcript). They showed that LUST is an antisense RNA, is a ncRNA and 
regulates RBM5 variant expression, and speculated that LUST functions to enhance full length 
RBM5+5+6 expression, which is then directed to the NMD, and suppresses 
RBM5+5+6t/Clone 26, thereby inhibiting cell death. In their model, they specifically proposed 
that the antisense ncRNA LUST forms a double-stranded RNA duplex with the alternatively 
spliced intron 5 and 6 retaining RBM5 transcript, soon after it emerges from the RNA 
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polymerase II transcription elongation complex 
149
. However, the biological function of LUST 
remains poorly studied.  
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CHAPTER II: MATERIALS AND METHODS 
 
 
Cell culture 
 
Human LS174T (ATCC # CL-188) and SW480 (ATCC #CCL-228) colon cancer cell lines 
were obtained from CEINGE-Advanced Biotechnology (Naples, Italy) cell culture facility, 
where were maintained according to the original datasheet. Human HT-29 (ATCC #HTB-38) 
and CaCo2 (ATCC #HTB-37) colon cancer cell lines were purchased from ATCC and tested 
for mycoplasma contamination using LookOut Mycoplasma PCR Detection Kit (Sigma-
Aldrich) according to the standard protocol. HT-29 cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) (Cornig), 1% 
penicillin-streptomycin (Cornig) and 2% Glutamine (Cornig). CaCo2 cells were grown in 
DMEM medium supplemented with 20% FBS (Cornig) and 1% penicillin-streptomycin 
(Cornig). Both cell lines were grown in adherent conditions by standard methods at 37°C in 
5% CO2. The medium was changed twice a week, cells were passaged using 0.05% 
trypsin/EDTA (Cornig) and used at early passages. 
 
Flow-cytometry analysis and cell sorting  
 
Multi-color flow-cytometry was performed with anti-human monoclonal antibodies (MoAbs) 
that were conjugated with fluorescein isothiocyanate (FITC), phycoerythin (PE), 
allophycocyanin (APC) and phycoerythin-Cy7 (PE-Cy7). Cells were stained using FITC-
conjugated MoAbs against CD24, PE-coniugated MoAbs against CD166, APC-coniugated 
MoAbs against CD133 (BD Biosciences), and PE-Cy7-conjugated MoAb against CD44 
(BioLegend). An analysis buffer composed of RPMI without red phenol (Invitrogen), 1-2% 
FBS (Cornig) and 10U/ml DNase (Sigma-Aldrich) was used to prepare cells for the analysis. 
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Enzymatically individualized cells were counted, resuspended in analysis buffer at 5 x 10
6
 
cells/ml and stained by incubation at 4°C for 20 min with the appropriate MoAbs. For FACS 
analysis, cells were stained in a 100μl labeling volume using the following concentrations, 
respectively: 0.1:10 for CD44 and 0.5:10 for CD24, CD133 and CD166. Samples were 
washed twice with analysis buffer, centrifuged and resuspended in 0.5ml of FACS flow sheath 
fluid (BD Bioscience). Immediately before FACS acquisition, cells were incubated at room 
temperature in the dark with DAPI (Invitrogen) to exclude dead cells. All experiments 
included a negative control to exclude the signal background caused by cellular auto-
fluorescence.  
Fluorescence-activated cell sorting of HT29 cells was performed after cells were 
enzymatically individualized, resuspended at 5 x 10
7
 cells/ml in sorting buffer (RPMI without 
red phenol (Invitrogen), 1-2% FBS, 10U/ml DNase, 2.5mM EDTA)) and stained by 
incubation with CD24 and CD44 MoAbs at 4°C for 20 min. After the staining, cells were 
washed twice with sorting buffer and resuspended at 2 x 10
7
 cells/ml. The samples were 
sequentially filtered (50μm, Partech) and incubated for 5 min in the dark with a vital dye, 
DAPI (Invitrogen).  
Samples were analyzed on a BD LSRII four lasers flow-cytometer (Bekton Dikinson, Franklin 
Lakes, NJ, USA). For each sample run, 10
4
 to 2 x 10
4
 events were recorded and analyzed. HT-
29 live cells sorting experiments were performed using BD FACSAria III using a 70μm 
nozzle. Sorted cells were collected in DMEM medium supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2% Glutamine.  
 
Analysis of cytometric data was performed using FACSDiva software (Bekton Dikinson). A 
three-gating strategy to define the target cell population was defined. Cells were initially gated 
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on a two physical parameters dot plot measuring forward scatter (FSC) versus side scatter 
(SSC) to exclude most of the dead cells and debris. Second, doublets were excluded by gating 
cells on FSC-height versus FSC-area dot plots. The last gate was used to exclude dead cells, 
based on DAPI expression.  Finally, cells were gating according to their Bright or Dim co-
expression of CD24 and CD44. 
 
In vitro Colonospheres formation assay 
 
The ability of the cells of forming colonospheres is strictly dependent on their stemness 
potential. In particular, cells enriched on stemness markers are able to grow in serum-free 
media, in a non-adherent manner and are able to generate colonospheres 
22,23,26
. Colonospheres 
formation assay was performed as previously described 
158
. Briefly, cells originating from the 
total HT-29 colon cancer cell line, or HT-29 sorted cells were plated at a density of 30,000 
cells/ml in stem cell medium, using low attachment plates (Corning). Stem cell medium 
(SCM) was composed of 1:1 ratio of DMEM/F12 (Gibco), 1% penicillin/streptomycin 
(Cornig), 2ml 50X B27 supplement (Invitrogen), 4μg/ml heparin (Fisher), 1% (w/v) of non-
essential amino acids (Cornig), 1% (w/v) of sodium pyruvate (Cornig), 1% (w/v) of L-
glutamine (Cornig), 10ng/ml FGF, 20ng/ml EGF, 1X growth factor mix (Growth factor mix 
10X: 100mL DMEM/F12, 4ml 30% (w/v) glucose, 200mg transferrin, 50mg insulin in 18ml 
of water and 2ml of 0.1N HCl, 19.33mg putrescine (sigma) in 20ml water, 200μl 0.3M sodium 
selenite, 20μl 2mM progesterone (Sigma), H2O to 200ml).  Cells were passaged every 7 days 
through enzymatic sphere disruption. Briefly, spheres were collected, gently centrifuged for 3 
min at 1300 r.p.m. and then washed with PBS. The pellet was resuspended in 1ml of 1X 
trypsin/EDTA and pipet up and down for 3 minutes, before incubating the cells for 3 min at 
37°C and 5% CO2. After incubation, an equal volume of SCM was added to quench the 
  28 
reaction. Cells were subjected to a second centrifugation to eliminate residual trypsin and then 
resuspended in 1 ml of SCM. Trypan blue was used to count the number of viable cells.  Cells 
were passaged for 7 weeks and then induced to differentiate by using DMEM supplemented 
with 10% FBS, 1% penicillin-streptomycin, and 2% Glutamine.  
 
RNA extraction, cDNA synthesis and qRT-PCR 
 
Total RNA was extracted from HT29, CaCo2 and HT29 derived colonospheres using Trizol 
and the RNeasy MiniKit (Qiagen) according to the manufacturer’s protocol. One to five μg 
total RNA was reverse transcribed using PrimeScript RT Reagent kit (Takara #6130). Briefly, 
the RNA was incubated for 5 min at 65°C, in a final volume of 10μl with 10mM dNTP 
mixture and 50μM of Random 6mers. Subsequently, the template RNA Primer Mixture was 
mixed with 5X PrimeScript Buffer, 40U/μl RNase Inhibitor and 200U/μl PrimeScript RTase 
in a final volume of 20μl. The reaction mixture was incubated immediately under the 
following conditions: 30°C for 10 min, 42 °C for 60 min and inactivation step at 70°C for 15 
min. Alternatively, the SuperScript VILO™ cDNA Synthesis Kit (Life Technologies) was 
used for low amount of RNA input. Quantitative PCR (qRT-PCT) was performed using the 
GoTaq qPCR Master Mix (Promega) on the Stratagene Mx3005P Real-Time PCR System 
(Agilent Technologies). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was 
used as housekeeping gene for normalization. Sequences of the primers used for qRT-PCR are 
listed in Table 1.2.  
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Table 1.2: List of primers used for qRT-PCR 
 
RNA-seq library preparation 
 
RNA-seq library preparation was performed at the Weill Cornell Medical College Genomic 
Core facility (New York) using the TrueSeq RNA sample preparation kit (Illumina RS-122-
2001) as per manufacturer recommendations. Samples were sequenced by the Illumina HiSeq 
2500 platform (Illumina) as 100 bp pair-ended reads. 
 
RNA-seq and Gene Ontology (GO) analysis 
 
Contaminant (aligned) RNA-seq reads were filtered with Bowtie software 
159
 and aligned to 
several human reference databases including the human genome (hg19, Genome Reference 
Consortium GRCh38), RefSeq exons and splicing junctions using BWA alignment algorithm 
(http://bio-bwa.sourceforge.net/) 
160
. The reads that were uniquely aligned to the exon and 
splicing-junction sites for each transcript were then counted as expression level for a 
corresponding transcript and were subjected to log2 transformation and global median 
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normalization. Differentially expressed genes were identified by the R package DEGseq 
161
 
using a false discovery rate (FDR) < 0.001 and fold-change >1.5. Gene ontology analysis was 
performed using the web tool The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) 
162,163
. 
 
Human LncProfiler qPCR array 
 
The LncProfiler
TM
 Kit (System Biosciences) is produced to tag and convert small non-coding 
RNAs into detectable and quantifiable cDNAs. The kit includes assays in pre-formatted plates 
for 90 well-annotated human lncRNAs, with 5 endogenous reference RNA controls as 
normalization signals. All of the lncRNAs on the qPCR array have validated primer sets for 
well-annotated lncRNAs that are registered in the lncRNA database created by Dr. John 
Mattick (www.lncrnadb.org). Briefly, 1μg of total RNA extracted from CD24Bright/CD44Bright 
and CD24
Dim
/CD44
Dim
 HT-29 sorted cells was diluted to 200~400ng/μl. 5μl Total RNA were 
combined with 2μl 5X PolyA Buffer, 1μl 25mM MnCl2, 1.5μl 5mM ATP and 0.5μl PolyA 
Polymerase in a final volume of 10μl. The reaction mix was then incubated for 30 min. at 
37°C. After the PolyA Tail step, 0.5μl of Oligo dT Adapter were added to the mix to induce 
the annealing of anchor dT adapter, heating the mix for 5 min. at 60 °C. Once the mix was 
cooled down at room temperature for 2 min., 4μl 5X RT Buffer, 2μl dNTP mix, 1.5μl 0.1M 
DTT, 1.5μl Random Primer mix and 1μl of Reverse Transcriptase were added to the mix to 
induce cDNA synthesis, and the reaction was incubated for 60 min at 42°C and heat for 10 
min at 95°C. Following the cDNA synthesis, the qRT-PCR reaction was set up using 1,750μl 
2X SYBR Green, 20μl LncRNA cDNA (from the previous step) and 1,730μl of RNase-free 
water in a total volume of 3,500. 28μl of Mastermix and 2μl of LncRNA primers per well 
were aliquoted in the qPCR plate. The qPCR reaction was set up using the fallowing steps: 
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1. 50°C 2 min. 
2. 95°C 10 min. 
3. 95°C 15 sec. 
4. 60°C 1 min. 
(40 cycles of Stage 3) 
A Dissociation Stage after the qPCR run was added to assess the Tm of the PCR amplicons to 
verify the specificity of the amplification reaction.  
qRT-PCR results were analyzed and ΔΔCT was evaluated using the array related software 
www.systembio.com/LncRNA.  
 
LncRNA LUST knockdown  
 
LncRNA LUST knockdown was performed using LNA longRNA GapmeR in vitro standard 
(Exiqon, #300600). LNA
TM
 longRNA GapmeRs are antisense oligonucleotides with perfect 
sequence complementary to their target RNA. When introduced into the cells, they sequester 
their target RNA in highly stable DNA:RNA heteroduplexes, leading to RNase H mediated 
target degradation. The sequences of the oligonucleotides and their LNA
TM
 spiking patterns 
were carefully designed by Exiqon’s GapmeR Design Algorithm 
(http://www.exiqon.com/ls/Pages/GDTSequenceInput.aspx?SkipCheck=true) to achieve high 
target affinity with excellent sequence specificity and biological stability. Four different 
probes directed against lncRNA LUST transcript and one unspecific Negative control probe 
were used.  
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LncRNA LUST cloning and overexpression  
 
The construct pcDNA3-LUST was made as previously described 
149
 with some modifications: 
LUST was amplified from 100ng of HT-29 DNA by PCR using 0.5μM of FactorXFBamHI 
(5′-CGGGATCCAAATGCCGCCACAGACTTTCA-3′) and 0.5μM of FactorXRNotI (5′-
ATGCGGCCGCCAGAAGAATCGCTTGAATCC-3′) primers. The PCR reaction was 
performed according to the fallowing conditions: 95°C for 5 min., 35 cycles at 95°C for 30 
sec., 55°C for 45 sec., 72°C for 80 sec., and a final step at 72°C for 5 min. The amplified 
product was visualized on 1.5% agarose gel and the corresponding 1.3 kb band was cut and 
purified. The product was digested with BamHI and NotI restriction endonucleases (New 
England Biolabs) at 37°C for 1h and purified. Subsequently, the insert was ligated into the 
pcDNA3 expression vector (Invitrogen) using T4 DNA Ligase (Invitrogen); the ligation 
reaction was performed for 15 min. at room temperature. Competent cells were transformed 
with 1μl of ligated vector pcDNA3-LUST and grown overnight at 37°C on plates coated with 
agar, supplemented with 1% ampicillin. A second batch of competent cells was transformed 
using the digested vector as control. The day after, 12 different colonies from pcDNA3-LUST 
agar plate, were picked and grown overnight at 37°C, 250 r.p.m. Plasmid DNA was extracted 
using NucleoSpin Plasmid kit (Macherey-Nagel) and submitted for sequencing.  
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TOPFlash dual luciferase assay  
 
HT-29 cells were seeded at a density of 0.25 x 10
5
 cells/well in 12-well plates one day before 
transfection. Cells were transiently transfected using Lipofectamine (Invitrogen) according to 
the manufacturer’s instructions, using 250ng of the TOPFlash reporter gene construct (M50 
Super 8x TOPFlash, Plasmid #12456, Addgene) and 500ng of pcDNA3-LUST and/or 500ng 
of pcDNA-β-Catenin construct. 48h after transfection, cells were collected and lysed for 15 
min. at room temperature. 20μl of each lysate was used to measure luciferase reporter gene 
expression (Dual-luciferase Reporter assay System, Promega). The luciferase activity was 
normalized to Renilla luciferase activity from co-transfected internal control plasmid pRL-
CMV.  
 
Western blot  
 
For western blot analysis, 30μg of protein lysate were analyzed by SDS-PAGE, transferred to 
PVDF membranes (Bio-Rad) and blotted with indicated antibodies followed by ECL detection 
(Thermo Scientific). Western blot assays were performed using the fallowing commercially 
available antibodies, at the indicated concentrations: anti–β-actin (Sigma, A5441, 1:1,000), 
anti-α-tubulin (Sigma, T5168, 1:1,000), anti-β-catenin (Bethyl Laboratories, A302-012A, 
1:1,000), anti-active-β-catenin (Millipore, 05-665, 1:1,000), anti-cyclin D1 (CCND1, Abcam, 
ab16663, 1:1,000), anti-c-myc (Cell Signaling, 5605, 1:1,000).  
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Tansfections 
 
For lncRNA LUST knockdown, 1.8 x10
5
 HT-29 cells/well were seeded in a 6-well plate and 
transfected using 300pmole of LNA GapmeRs and Lipomefctamine 2000 according to the 
manufacturer’s protocol. After 48 h, cells were harvested and RNA and protein were collected 
for qRT-PCR and western blot assays.  
 
For lncRNA LUST overexpression, pcDNA3 and pcDNA3-LUST construct were transiently 
transfected into HT-29 cells grown at 30-50% confluence in 100mm
2
 culture dishes, washed 
with OPTI-MEM media (Invitrogen). 4μg of DNA, mixed with 20μl PLUS Reagent 
(Invitrogen), 20μl of Lipofectamine Reagent (Invitrogen) and 6.5 ml of OPTI-MEM media 
were added to the cells. Transfectants were incubated at 37°C for 18h, after which media was 
replaced with DMEM supplemented with 10%FBS, 1% pennicilin/streptomycin and 2% 
Glutamine. RNA and proteins were collected 24h after transfection to perform qRT-PCR and 
western blot, respectively.  
 
For colonospheres formation assay, cells transiently transfected with pcDNA-LUST were 
trypsinized and collected 24h after transfection and seeded in a low-attachment plate at 30,000 
cells/ml according to the methods previously described.  
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Nuclear/Cytoplasmic RNA fractionation 
 
For nuclear/cytoplasmic RNA fractionation, HT29 and CaCo2 cells were washed twice and 
harvested in PBS. After centrifugation at 4°C for 5 min. at 1400 r.p.m, the supernatant was 
removed and the pellet resuspended in 500μl of RNA Lysis Buffer 1X (2X Lysis Buffer: 
280mM NaCl, 3mM MgCl2, 20mM TrisHCl pH 7.5, 0.1% NP40 (igepal)).  An equal volume 
of RNA Lysis Buffer/Saccarose (2X RNA Lysis Buffer, Sucrose 50%) was added at the 
bottom of a 1.5 ml eppendorf tube to achieve two separate phases, and combined with the cell 
lysate. After centrifuging at 4°C for 10 min. at 13,000 r.p.m., the nuclei were obtained by 
deposition at the bottom of the tube, and the cytoplasm at the top. 450μl of the cytosolic 
fraction were collected with a 0.5ml syringe and the rest was removed leaving the pellet intact 
(nuclear fraction). 1ml of Trizol was wadded to the cytosolic fraction, while the nuclear 
fraction was first resuspended in 450μl of RNA Lysis Buffer 1X and 1mL of Trizol was 
subsequently added. RNA was extracted fallowing the Trizol manufacturer’s instructions.  
 
RNA-Fluorescence In Situ Hybridization (RNA-FISH) 
 
For lncRNA LUST localization, RNA-FISH was performed fallowing Barakat’s protocol with 
some modifications 
164
. Cells were first transiently transfected with pcDNA3 or pcDNA3-
LUST construct. 48 h post-transfections, cells were harvested and seeded on glass coverslips 
the day before the experiment. Cells were washed shortly with PBS and then fixed in 4% 
formaldehyde/5% acetic acid in PBS for 15 min. Subsequently, two washes with PBS and 
treatment with pepsin (0.1% in 10mM HCl) for 5 min. at 37°C, fallowed by two additional 
washes with water were performed. Cells were dehydrated using 70% ethanol for 3 min. 90% 
ethanol for 3 min., 100% ethanol for 3 min. and then let air dry for several minutes. 4.7μl of 
double-DIG labeled custom LNA mRNA detection probe (Stock concentration 84.4μM, 
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Exiqon) were put on a slide and covered with a 18x18 mm cover slip. The probe was 
denatured at 80°C for 75 sec, and the hybridization induced for 30 min. in a humid chamber, 
at hybridization temperature of 54°C (hybridization temp= Tm probe- 21°C).  Cells were 
dehydrated as before and the hybridized probe was spot on a glass side and incubated with a 
coverslip on the top. Slides were placed in a humidified chamber filled with 50ml 50% 
formamide/2x Saline Sodium Citrate buffer (SSC: 3M NaCl, 300mM trisodium citrate pH 7), 
and incubated overnight at 37°C. The day after, a 6-well plate was filled with 2x SSC and pre-
warm till 42°C. Coverlisps were added after overnight incubation and subsequently incubated 
at 42°C for 5 min. 2x SSC was removed and a further incubation with 50% formamide/2x SSC 
for 10 min at 42°C was performed, for 3 times. Slides were washed with Tris-saline-Tween 
(TST) for 2 x 5 min. at room temperature. Coverlisps were incubated upside down for 
blocking with 50μl of Tris-Saline-BSA (TSBSA), during 30 min. at room temperature in a 
TST-humidified dark chamber, and then transferred to a 6-well plate for two washes of 5 min. 
each with TST. Incubation with 50μl of mouse anti-DIG antibody (1:100 in TSBSA, Abcam) 
first, and with anti-mouse secondary antibody then, was subsequently performed for 30 min. at 
room temperature in the same way. Cells were dehydrated through 70% ethanol for 3 min. 
90% ethanol for 3 min., 100% ethanol for 3 min. and let air dry for several minutes. Finally, a 
drop of mounting media mixed with DAPI, was used to mount the coverslips on each glass 
slide, sealed with nail polish and analyzed with Leica DM6000 microscope.  
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RNA Immuno-Precipitation (RIP) assay 
 
Briefly, RNA is first cross-linked to proteins by formaldehyde, protein of interest is immune-
precipitated by a specific antibody, then the cross-linking is reversed, and RNA is isolated and 
prepared for analysis 
165
. In particular, Dynabeads® Protein G for Immuno-precipitation 
(Invitrogen), were washed twice and resuspended in 500μl RIPA buffer (150 mM NaCl, 1.0% 
NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50mM Tris–HCl (pH 7.4), 1.0mM EDTA).  
5μg of antibody against β-Catenin (Rabbit, Bethyl Laboratories) and non-specific IgG (Rabbit, 
Abcam) were added to the beads and incubated for 2 h at 4 °C with gentle rotation. HT-29 and 
CaCo2 cells were grown at ~90% confluence and harvested by trypsinization. An equivalent 
amount of media was added to quench the reaction and cells were collected in a 15ml conical 
tube and pellet by centrifugation at 500 x g for 10 min. Cells were washed twice with PBS and 
collected after each wash by pelleting at 500 x g for 5 min. The pellet was resuspended in 10 
ml PBS and cells were counted using Trypan Blue. Cross-linking was performed by adding 
37% formaldehyde to a final concentration of 0.3%, incubating the plates for 10 min., with 
gentle rotation at room temperature. The cross-linking reaction was quenched by adding 
1.25M glycine to a final concentration of 0.125M, incubating the plates at room temperature 
for 5 min. Cells were collected and pelleted by centrifugation at 500 x g for 5 min, then 
washed twice, each time with 10ml of 1X PBS, spin and pellet as before. The pellet was 
resuspended in 2.2ml of RIPA buffer, supplemented with protease (Complete EDTA-free 
Protease Inhibitor Cocktail tablets, Roche) and RNAse (Recombinant RNasin Ribonucelase 
Inhibitor, Promega) inhibitors. The lysis was performed incubating at 37°C for 30 min., 
vortexing every 5 min. for 30 sec. intervals for the duration of the incubation. The sample was 
homogenized using a dounce homogenizer and the lysate was centrifuged at maximum speed 
(≥10,000 x g) using a microcentrifuge for 10 min. Supernatant was collected and the pellet 
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discarded. Lysate was pre-cleared using 30μl of protein G beads for 1h with gentle rotation at 
4°C. Beads previously incubated with antibody were washed twice with 500μl of RIPA buffer 
and a 100μl aliquot of lysate was set apart to be used as Input sample. The rest of the lysate 
was divided between the two antibody-mounted beads (1ml each) and incubated overnight at 
4°C with gentle rotation. The day after, the supernatant was removed by using a magnetic rack 
and the beads were washed four times with high salt RIPA buffer (1.0 M NaCl, 1.0% NP-40, 
0.5% Sodium deoxycholate, 0.1% SDS, 50mM Tris–HCl (pH 7.4), 1.0mM EDTA). 50μl of 
sample were set apart to ensure that the antibody used worked and western blot analysis was 
performed. The remaining beads were resuspended in 100μl of Buffer C (150mM NaCl, 
50mM Tris–HCl (pH 7.4), 5mM EDTA, 10mM DTT, 1.0% SDS), supplemented with 10μg of 
proteinase K (Fisher Bioreagents); 100μl of buffer C and proteinase K were also added to the 
input sample, and the reactions were incubated for 30 min. at 42°C for proteinase K digestion. 
A subsequently incubation for 4h at 65°C was performed to reverse the formaldehyde cross-
links. After reverse cross-linking, 400μl of Trizol were added to the samples and RNA 
extraction was performed according to the manufacturer’s protocol. cDNA synthesis was then 
performed as previously described.  
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UV Cross-Linking and Immuno-Precipitation (CLIP) assay 
 
CaCo2 cells were cultured under normal growth conditions. Following UV cross-linking 
isolation of chromatin was performed using standard nuclear chromatin isolation techniques 
166
. CLIP was performed essentially as described previously 
167
 with modifications described 
below. CaCo2 cells were harvested by trypsinization and resuspended in 1ml PBS, 1ml of 
nuclear suspension buffer (1.24M sucrose; 40mM Tris-HCl pH 7.5; 20mM MgCl2; 4% Triton 
X-100), and 3ml water on ice for 20 min. Nuclei were pelleted by centrifugation at 2,500 x g 
for 15 min. and resuspended in a CLIP buffer (150mM KCl, 25mM Tris pH 7.4, 5mM EDTA, 
0.5mM DTT, 0.5% NP40, 9μg/ml leupeptin, 9μg/ml pepstatin, 10μg/ml chymostatin, 3μg/ml 
aprotinin, 1mM PMSF, 100U/ml RNAse inhibitor; Ambion). The nuclear suspension was 
sheared using a bounce homogenizer with the B pestle using 10 strokes followed by 5 minutes 
of sonication (Bioruptor, Diagenode) at 4°C. Nuclear debris was pelleted by centrifugation at 
15,000 rpm for 10 min. Once DNA tags were obtained and found within the appropriate 
nucleotide size range, samples were subjected to RNase-free DNA hydrolysis (Turbo DNAse, 
Ambion) and protein-RNA complexes were subjected to immuno-precipitation for CLIP. 
100mg of antibodies for Cbx7 (Barradas et al., 2009), EZH2, β-Catenin, (Bethyl 
Laboratories), or TCF4 (Bethyl Laboratories) were added separately to supernatant and 
incubated for 2 h at 4°C with gentle rotation. Forty microliters of protein A/G beads were 
added and incubated for 1 h at 4°C with gentle rotation. Beads were pelleted at 2,500 rpm for 
30 sec., the supernatant was removed, and beads were resuspended in 500 ml RIP buffer and 
repeated for a total of three washes in CLIP buffer, followed by one wash in PBS. Chromatin-
bound RNA was then extracted from protein using Trizol and subsequently used for cDNA 
synthesis.  
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Statistical Analysis 
All experiments were performed in triplicate at least 3 times. All values were expressed as 
mean ± SEM. Statistical analysis was performed by the Unpaired Student’s t test. A 
probability value of p < 0.05 was considered statistically significant.   
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CHAPTER III: RESULTS 
 
 
3.1 CD24 and CD44 expression defines the CCICs subpopulation in HT29 colon cancer 
cell line, and is upregulated during colonospheres formation 
 
Previous studies showed that the detection of surface antigens such as CD24, CD44, CD133 
and CD166 can be used to characterize and isolate the CCICs population in colon cancer cell 
lines 
21,23,33
. Therefore, I first confirmed the expression of these stemness markers on 3 
different colon cancer cell lines chosen for their differentiated status: SW480 (poorly 
differentiated), HT29 (moderately differentiated) 
168
 and LS174T (well differentiated) 
169
. As 
shown in Figure 1.3, within the HT-29 cell line is it possible to identify a single 
subpopulation co-expressing all four stemness markers with bright intensity (CD24, CD44, 
CD133 and CD166, Fig. 1.3, top right panel, green subpopulation previous gated on 
CD24
Bright
/CD44
Bright
 intensity, top left panel). The same gating strategy was applied to 
LS174T and SW480 colon cancer cell lines, and as it shown, two different subpopulations 
could be discriminated based on the intensity of CD24 and CD44 co-expression (middle and 
bottom left panels), but the intensity of CD133 and CD166 antigens results to be lower (Fig. 
1.3 middle and right panels) compared to that of the HT-29 subpopulation. Taken together 
these results show that HT-29 cell lines could represent a better tool to study the role of the 
cancer initiating cells in colon cancer. 
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Figure 1.3 : Fluorescence-activated cell sorting (FACS) analysis  
Intensity expression of CD24 (FITC), CD44 (PE-Cy7), CD133 (APC) and CD166 (PE) surface 
antigens on 3 different adherent colon cancer cell lines: HT29, LS174T and SW480. Histograms report 
the mean fluorescence intensity (MFI, range 0-10,000) of CD133 and CD166. 
 
 
 
To assess the ability of self-renewal of differentiated versus undifferentiated subpopulations in 
HT-29 cells, I performed in vitro colonospheres formation assay as previously described 
1,33
. 
To this purpose, I isolated HT29 CD24
bright
/CD44
bright
 (CCICs) and CD24
dim
/CD44
dim  
(the 
more differentiated counterpart) by Fluorescence-activated cell sorting (FACS) (Fig. 2.3). 
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Figure 2.3 : Sorting of CCICs and more differentiated counterpart in HT-29 cancer cell line 
Populations were gated using the CD24 (FITC) and CD44 (PE-Cy7) Bright and Dim expression. The 
percentage of selected subpopulations is shown.  
 
Sorted cells were then growth in suspension, in serum-free media, to induce colonospheres 
formation 
1
. Figure 3.3 shows that the CD24
bright
/CD44
bright 
subpopulation is able to form 
more colonospheres compared to the CD24
dim
/CD44
dim 
subpopulation. Of note, colonospheres 
obtained from CCICs are larger in terms of number and size, compared to the ones obtained 
from the more differentiated counterpart (Fig. 3.3, left and right panel, respectively).  
 
Figure 3.3 : HT-29 Colonospheres obtained from CCICs and the more differentiated counterpart 
Left: colonospheres obtained from CCICs; right: colonospheres obtained from the more differentiated 
counterpart. Cells are cultured in ultra-low adherent conditions. 
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Taking together, these observations confirmed that the bright expression of CD24 and CD44 
stemness markers could be used to isolate colon cancer initiating cells from HT-29 colon 
cancer cell line 
33
. 
 
3.2 Wnt-target genes are induced within CCICs compared to the more differentiated 
counterpart  
 
It is largely accepted that the Wnt/β-catenin signaling is the most deregulated pathway in colon 
cancer. Furthermore, previous studies have shown that this signaling regulates, specifically, 
the growth and maintenance of colonospheres 
170,171
; in particular, formation of colonospheres 
from colon cancer stem cells subpopulations is associated to an elevated Wnt-signaling 
activity 
171
. Based on these findings, I performed RNA-Seq on CD24
bright
/CD44
bright
 (CCICs) 
and CD24
dim
/CD44
dim  
(the more differentiated counterpart) subpopulations from HT-29 colon 
cancer cell line, and on colonospheres derived from the CD24
bright
/CD44
bright
 subpopulation, to 
explore pathways that could be eventually deregulated. Results showed that approximately 
3000 genes were elevated in CCICs compared to the more differentiated counterpart, indicated 
with a fold change >1.5 (Fig. 4.3, left upper panel). The Gene Ontology analysis of the 
elevated genes revealed that a majority of them are involved in regulation of cell proliferation, 
response to hormone stimulus (hormone receptors), regulation of programmed cell death, 
positive regulation of cell migration and other biological processes characteristic of cancer cell 
phenotype (Fig. 4.3, left lower panel). The results also displayed that approximately 2000 
genes are down-regulated between CD24
bright
/CD44
bright
 and CD24
dim
/CD44
dim 
subpopulations 
(Fig. 4.3, upper right panel), and gene ontology analysis revealed that a majority of them are 
also involved in regulation of cell proliferation, regulation of system process or other 
mechanisms involved in metabolism (Fig. 4.3, lower right panel).  
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Figure 4.3: RNA-Seq analysis of CD24
Bright
/CD44
Bright 
and CD24
Dim
/CD44
Dim
 subpopulations 
Upper panels: number of induced or up-regulate (left) and down-regulated (right) genes with a >1.5 fold 
change between CD24
Bright
/CD44
Bright 
and CD24
Dim
/CD44
Dim
 subpopulations. Lower panels: gene ontology 
analysis of induced or up-regulated (left) and down-regulated genes (right).  
 
 
To gain more detail of the characteristics linked with stemness versus differentiation, I 
analyzed the expression of genes defining differentiation or stem cell character, and the results 
showed that genes involved in mesenchymal cells differentiation, such as Mucin 2  (MUC2) 
172
 or Keratin B20 (KB20/KRT80) 
173
 are down-regulated, while colon cancer stem cells 
markers, in particular CD24, CD44, CD166 and ALDH1A1 are up-regulated (Fig. 5.3, shown 
as the green and red bars, respectively). Furthermore, members of the canonical Wnt-
mediated signaling such as ASCL2, IGFBP2, LGR4, DKK1, MYCL1, FGFR2, SP5, MMP7 and 
the receptor EPHB3 were elevated in the CCICs compared to the more differentiated 
counterpart, with a fold increase >1.5 (Fig. 5.3, shown as the blue bars).  
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Figure 5.3: Expression of differentiation genes, CSCs markers and Wnt-signaling genes 
Differential expression of differentiation genes (green), CSCs markers (Red) and Wnt-signaling genes (blue) 
between CD24
Bright
/CD44
Bright 
and CD24
Dim
/CD44
Dim
 subpopulations. Fold change >1.5 p<0.01 
 
 
 
Next, I validated and confirmed through qRT-PCR, the overexpression of some of the most 
relevant Wnt-mediated target genes that play a pivotal role in colon cancer stem cells 
maintenance, and in particular the ones that regulate proliferation as Cyclin D1 (CCND1) and 
MYC, and the leucine-rich repeat containing G protein-coupled receptor 4 (LGR4), strong 
Wnt-mediated enhancer (Fig. 6.3).  
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Figure 6.3: Wnt-mediated target genes expression between CCICs and differentiated cells 
qRT-PCR validation of Wnt-mediated target genes differential expression between CCICs and the more 
differentiated counterpart. 
 
HPRT was used as housekeeping control gene for normalization. Error bars 
indicate the standard error of the mean (SEM). *p<0.05 
 
 
 
I also performed RNA-Seq on colonospheres and compared the expression of Wnt-target 
genes and stemness markers with the parental subpopulation (CD24
bright
/CD44
bright
) they were 
originated from. My results showed that the expression of ASCL2, MYCL1, LGR4, EPHB3, 
CLDN1, CD44, CD24, ALDH1A1 and AKR1B10 was strongly increased during colonospheres 
formation. What became of interest to me was that genes involved in differentiation, i.e. 
Krueppel-like factor 9 (KLF9) 
174
, KB20 
173
 and the β-catenin regulated gene Peptidyl 
Arginine Deiminase, Type 1 (PADI1) 
175,176
, were the most down-regulated (Fold change 
>1.5) gene transcripts in both, colonospheres and the parental subpopulation, as well as the 
retinoic acid receptor responder protein 1 (RARRES1), known to have a tumor suppressor role 
177
. Intriguingly, two lncRNAs: Kcnq1ot1 and LUST, resulted to be increased in this process, 
although the overexpression of LUST seemed to be more interesting because specific of the 
colonospheres formation process (Fig. 7.3).  
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Figure 7.3: Heat map showing upregulated and down-regulated genes in CCICs 
A Heat map showing up-regulated or induced genes (red) and down-regulated genes (blue) in 
CD24
Bright
/CD44
Bright
 compared to CD24
Dim
/CD44
Dim 
subpopulations,
 
and in colonospheres compared to 
CD24
Dim
/CD44
Dim
 subpopulation. Fold change >1.5  p<0.01 
 
 
 
These results show that Wnt-signaling is highly active during colonospheres formation. 
Therefore, I speculated that the expression of Wnt-target genes should be reduced in FBS-
induced differentiation cells. To confirm this hypothesis, I evaluated the expression genes 
directly responsive to Wnt-signaling in colonospheres and FBS-induced differentiation. 
Figure 8.3 shows that the mRNA levels of CCDN1, LGR4 and MYC were reduced when cells 
were induced to differentiate (Fig. 8.3).  
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Figure 8.3: Wnt-mediated target genes expression in colonospheres differentiated cells 
Validation by qRT-PCR of Wnt-mediated target genes differential expressed in colonospheres and FBS-
induced differentiation cells. HPRT was used as housekeeping control gene for transcript normalization. 
Error bars indicate the standard error of the mean (SEM). *p<0.05 
 
 
Taking together, these observations show that the Wnt-signaling is strongly active during 
colonospheres formation and that the activity is reduced upon FBS-induced differentiation 
confirming its role in colonospheres maintenance 
170
.  
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3.3 The stemness capability of CCICs is strongly related to lncRNA LUST expression  
 
Recent data have shown that deregulation of coding as well as non-coding RNAs, such as 
miRNAs and lncRNAs can contribute to cancer initiating cells generation (Reviewed in 
178-
180
). Lately, it has been demonstrated that, in cancer, the Wnt-signaling can be additionally 
regulated by lncRNAs through cell-autonomous mechanisms 
181-183
. In order to investigate the 
involvement of lncRNAs in colon cancer initiating cells maintenance and their role in the Wnt-
signaling regulation, I first performed a lncRNAs profiler array analysis on CCICs and the 
more differentiated counterpart isolated from HT-29 colon cancer cell line. Results from the 
array show that several lncRNAs were upregulated in CCICs compared to the differentiated 
counterpart. Table 1.3 shows the most upregulated lncRNAs in CCICs, with a fold increase 
higher than 2.5.   
 
Table 3.1: lncRNAs up-regulated in CCICs compared to the differentiated counterpart 
 
 
  51 
Among these lncRNAs, LUST was found to be overexpressed also in colonospheres by RNA-
Seq, suggesting a functional role played in the colonospheres formation (Fig. 7.3).  
To address the functional role of LUST on cancer stem cell maintenance, I performed in vitro 
colonospheres formation assay and analyzed by qRT-PCR the lncRNA and stemness markers 
expression in colonospheres and FBS-induced differentiation cells. As shown in Figure 9.3 
(left), the lncRNA LUST is strongly increased, as expected from the RNA-Seq and lncRNA 
profiler array data. Of note, the increase appears to be significant already after 14 days in 
culture, when the stemness markers levels (Fig. 9.3, middle and right) are not increased yet, 
and reaches a 10 fold change increase when cells are grown for 5 weeks in the same 
conditions (Fig. 9.3, left). This result suggests that LUST upregulation could be an early event 
in the colonospheres formation. 
 
 
Figure 9.3: LUST lncRNA, CD24 and CD44 mRNA  expression levels in HT29 colonospheres 
LUST lncRNA, CD24 and CD44 mRNA levels in HT29 colonospheres, respectively after 14 and 35 days 
cultured in ultra-low attachment conditions. HPRT was used as housekeeping control gene. Error bars 
indicate the standard error of the mean (SEM). *p<0.05. 
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As expected, when colonospheres differentiation is induced by adding FBS 
23
, the mRNA 
expression levels of stemness markers CD24 and CD44 is abrogated (Fig. 10.3, left and 
middle panel), confirming the loss of the stemness potential. Interestingly, the expression level 
of LUST drastically decreases (Fig. 10.3, right panel).  
 
 
Figure 10.3: LUST lncRNA CD24, CD44 mRNA levels in FBS-induced differentiation cells 
LUST lncRNA, CD24 and CD44 mRNA levels in colonospheres and in FBS-induced differentiation cells. 
Gene relative levels were analyzed by qRT-PCR. HPRT was used as housekeeping control gene for 
normalization. Error bars indicate the standard error of the mean (SEM). *p<0.05 
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Furthermore, the loss of stemness markers is also shown at the protein level (Fig. 11.3, blue 
population).  
 
 
Figure 11.3: FACS analysis of Colonospheres and FBS-induced differentiation cells 
FACS analysis of Colonospheres (upper panels) and FBS-induced differentiation cells (lower panels) 
showing loss of expression of stemness markers (blue population). Histograms report the mean fluorescence 
intensity (MFI, range 0-10,000) of CD24 (FITC) and CD44 (PE-Cy7). 
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3.4 LUST knock-down impairs Wnt-target genes activation  
 
In order to investigate LUST involvement in Wnt-signaling, I silenced LUST expression in 
HT29 cells using locked nucleic acid (LNA) longRNA GapmeRs, which are single stranded 
antisense oligonucleotides (ASO) used for efficient inhibition of lncRNAs expression 
(Exiqon). Figure 12.3 shows, respectively, the 60% and 50% loss of LUST expression using 
two different ASOs, measured by qRT-PCR (Fig. 12.3 A). Interestingly, LncRNA LUST 
knockdown also reduces cells growth as shown in Figure 12.3 B. 
 
 
Figure 12.3: lncRNA LUST knockdown 
A) Knock-down of the lncRNA LUST. lncRNA expression is reduced, respectively, to 40% and 50% 
from ASO1 and ASO2. An ASO unspecific probe was used as negative control (ASO CTRL). HPRT 
was used as housekeeping control gene for normalization. Error bars indicate the standard error of the mean 
(SEM).  B) Cell growth reduction upon lncRNA LUST knockdown.  
 
 
 
To verify an involvement of LUST in Wnt-signaling regulation I analyzed the expression of 
Wnt-signaling target genes. My results showed that, interestingly, a strong reduction of several 
target genes such as AXIN2, CCND1, CD44, and TCF4 as well as CD24 mRNA levels occurs 
upon LUST knockdown (Fig. 13.3).  
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Figure 13.3: Wnt-signaling target genes expression in LUST knockdown cells 
mRNA levels of Wnt-mediated genes upon LUST knockdown were analyzed by qRT-PCR. HPRT was 
used as housekeeping control gene for normalization. Error bars indicate the standard error of the mean 
(SEM).  
 
 
 
Furthermore, Figure 14.3 shows a decrease also at the protein level of CCND1 and c-Myc. Of 
note, LUST knockdown caused a reduction of active β-catenin (Fig.14.3). 
 
Figure 14.3: Wnt-signaling member proteins levels in LUST knockdown cells 
WB analysis of total β-catenin, active β-catenin, c-Myc and CCND1 in ASO control cells and in LUST 
knockdown cells. 30μg of protein from total cell lysate were analyzed. α-tubulin was used as a loading 
control. 
 
Taken together, these results demonstrate that LUST regulates Wnt/β-catenin signaling. 
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3.5 LUST overexpression induces Wnt/β-catenin signaling activation  
 
I performed dual luciferase assay using M50 Super 8x TOPFlash promoter, which contains 
two sets of 3 copies of the wild-type TCF binding regions upstream of a luciferase reporter, 
transiently integrated in HT29 cells (TOPFlash-HT29 cells). Relative luciferase activity was 
measured in TOPFlash-HT29 cells transfected with pcDNA3-LUST, pcDNA3-β-catenin, or 
pcDNA3-LUST and pcDNA3-β-catenin.  
 
The results showed that the lncRNA LUST alone as well as β-catenin is able to activate TCF 
reporter. Interestingly, the co-transfection of pcDNA3-LUST and pcDNA3-β-catenin induced 
a really strong increase in luciferase activity. These results demonstrated that the lncRNA 
LUST and β-catenin synergistically activate Wnt/β-catenin signaling (Fig. 15.3).  
 
 
Figure 15.3: TOPFlash Luciferase Assay in LUST overexpressing cells 
Relative luciferase activity measured in TOPFlash-HT29 cells transiently transfected with pcDNA3-
LUST, pcDNA3-β-catenin, or pcDNA3-LUST and pcDNA3-β-catenin.  
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To further evaluate the LUST-mediated regulation of Wnt-signling in colon cancer, I analyzed 
the mRNA levels of Wnt-signaling target genes upon LUST overexpression. pcDNA3 and 
pcDNA3-LUST constructs  were transiently transfected into HT29 cells and RNA samples 
were analyzed through qRT-PCR. The results show the expression of AXIN2, CCND1 and 
TCF4 increased with a fold change of 2.8. The mRNA levels of the stemness markers CD24 
and CD44 are also upregulated in these conditions, with a fold increase of 2. Interestingly, the 
mRNA expression level of MYC is approximately 4 times higher compared with its expression 
in cell transfected with empty vector. These results confirm that LUST activates the Wnt-
signaling in colon cancer cells (Fig. 16.3). 
 
 
Figure 16.3: Wnt-signaling target genes expression in LUST overexpressing cells 
mRNA levels of Wnt-target genes upon LUST overexpression were analyzed by qRT-PCR. HPRT was 
used as housekeeping control gene for normalization. Error bars indicate the standard error of the mean 
(SEM).  
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Once I demonstrated that LUST overexpression induces activation of Wnt-signaling target 
genes transcription, I further investigated if the increase at the transcriptional level was 
reflected by a corresponding increase at the protein level. To this purpose, I analyzed by 
western blot the hypothetical changes of protein levels in lncRNA LUST overexpressing cells. 
As shown in Figure 17.3, total levels of β-catenin remain stable, while there is an increase of 
expression of active β-catenin, MYC and CCND1, demonstrating that the increase in induced 
at both, mRNA and protein levels. 
 
 
Figure 17.3: Wnt-signaling member proteins levels in LUST overexpressing cells 
WB analysis of total β-catenin, active β-catenin, c-Myc and CCND1 in LUST overexpressing cells and 
in pcDNA3 control cells. 30μg of protein from total cell lysate were analyzed. β-actin was used as a 
lading control.  
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3.6 LUST is a nuclear lncRNA that strongly binds to β-catenin  
 
To identify the molecular mechanism by which LUST regulates the Wnt-signaling, I performed 
nuclear/cytoplasmic RNA fractionation in HT29 colon cancer cell lines. My results indicated 
that LUST lncRNA localization is mostly nuclear in both cell lines, although a negligible 
amount of transcript is also detected in the cytoplasmic compartment of the cells (Fig. 18.3). 
Malat1, a nuclear lncRNA, was used as a positive control 
184
. 
 
 
 
 
Figure 18.3: HT29 Nuclear/Cytoplasmic RNA fractionation 
Bar plots show the relative abundance of LUST measured by qRT-PCR. Malat1 was used as positive control 
for nuclear localization. HPRT was used as housekeeping control gene for normalization. Error bars indicate 
the standard error of the mean (SEM).  
 
 
 
To further validate LUST cellular localization, we performed RNA Fluorescence In Situ 
Hybridization (RNA-FISH) in HT29 cells transiently transfected with pcDNA3 (empty vector) 
or pcDNA3-LUST. Results shown that in HT29 cells transiently transfected with pcDNA3-
LUST, the transcript expression is mostly nuclear (red spots) (Fig. 19.3). 
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Figure 19.3: RNA-FISH in HT29 colon cancer cells 
RNA-FISH on HT29 transfected with pcDNA3 (left) or pcDNA3-LUST (right). Nuclei are stained with 
DAPI (blue), lncRNA LUST was detected using LNA double-DIG mRNA probe (red). White arrow 
indicates the LUST transcript. 
 
 
The involvement of lncRNAs in colorectal cancer has been largely demonstrated and in 
particular, several studies demonstrated the interaction of lncRNAs with Wnt/β-catenin 
signaling in cancer 
185,186
. To analyze the role played by LUST in the regulation of β-catenin 
activity, I performed RNA Immuno-Precipitation (RIP) 
165
 in HT29 cell lines, immuno-
precipitating β-catenin and using IgG as negative control. Results demonstrated that the 
lncRNA LUST strongly binds to β-catenin as shown in Figure 20.3. 
 
Figure 20.3: RNA Immuno-Precipitation (RIP) of β-catenin in HT29 cells 
Left: Enrichment of lncRNA LUST binding to β-catenin protein. Enrichment is shown as % input. Right: 
RIP-WB to confirm β-catenin immuno-precipitation. IgG was used as negative control. Sup: supernatant. 
Error bars indicate the standard error of the mean (SEM). *p<0.05 
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To further confirm the binding of LUST with β-catenin, I performed Cross-Linking Immuno-
Precipitation (CLIP) assay 
167
 in CaCo2 colon cancer cell line, which harbors both, APC and 
β-catenin mutations 187.  
The CLIP experiment was performed by immune-precipitation of β-catenin, the transcription 
factor 4 (TCF4), Histone-lysine N-methyltransferase EZH2, and the chromobox protein 
homolog 7 (CBX7). β-catenin and TCF4 were analyzed because members of Wnt-signaling 
188
, while EZH2 was used as positive control for lncRNA-binding 
189
 and IgG and CBX7 as 
negative controls for Wnt-signaling. Interestingly, we were able to detect the binding of 
lncRNA LUST with β-catenin and TCF4 with a 2.5 and 1.8 fold change, respectively, 
compared to the IgG or CBX7 binding, used as negative controls (Fig. 21.3).  
 
Figure 21.3: Cross-Linked Immuno-Precipitation (CLIP) assay in CaCo2 colon cancer cells 
Enrichment of lncRNA LUST to β-catenin and TCF4 is shown. IgG and CBX7 were used as negative 
controls. Error bars indicate the standard error of the mean (SEM). *p<0.05 
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A supplemental validation of my results was obtained by performing RIP in CaCo2 as shown 
in Figure 22.3. 
 
 
 
Figure 22.3: RNA Immuno-Precipitation (RIP) of β-catenin in CaCo2 
Left: Enrichment of lncRNA LUST binding to β-catenin shown as % input. Righ: RIP-WB to confirm β-
catenin immuno-precipitation. IgG was used as negative control. Sup: supernatant. Error bars indicate the 
standard error of the mean (SEM). *p<0.05 
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3.7 LUST overexpression accelerates colonospheres formation of CCICs 
 
 
To demonstrate that LUST could be the key effector in colonospheres formation, I performed 
in vitro colonospheres formation from HT29 cells upon LUST overexpression. Figure 23.3 
shows that LUST overexpression promotes an earlier colonospheres formation, compared to 
the control. In fact, HT-29 cells begin to form colonospheres after 21 days cultured in serum-
free media. LncRNA LUST overexpressing cells, instead, are able to form colonospheres 
already after 7 days in the same culture conditions. The full colonospheres morphology is 
reached after only 14 days, instead of 21 days needed for the untransfected cells.  
 
 
Figure 23.3: Colonospheres formation in LUST overexpressing cells 
HT29 untransfected cells were cultured in ultra-low attachment conditions, in serum free media for 7, 
14 and 21 days. pcDNA3, and pcDNA3-LUST transfected  cells were cultured in the same conditions 
for 7 and 14 days. Colonopsheres are shown.  
 
These results, strongly confirmed that LUST promotes colon cancer initiating cells 
maintenance, enhancing the activation of Wnt-signaling through β-catenin binding. 
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CHAPTER IV: DISCUSSION 
 
 
Colorectal cancer (CRC) is the third most common cancer and the third cause of cancer death 
in the United States. This type of malignancy is considered one of the most complete 
examples of a hierarchically organized solid cancer dominated by a subpopulation of 
immature cells with specific molecular and functional features. Human colorectal cancer 
initiating cells (CCICs) were first isolated on the basis of CD133 expression and demonstrated 
to induce tumors in mice that recapitulate the original malignancy 
22,23
. During the past years, 
several groups have expanded the search for other surface markers of CCICs in hopes of 
finding specific biomarkers, which could serve as prognostic and therapeutic targets. Several 
CCICs markers and combined phenotypes have been described, including CD44 
21,30,31
, CD24 
and CD29 
27
 as markers, and CD24
+
CD44
+
 
33
, EphB2
high
 
190
, EpCAM
high
/CD44
+
/CD166
+
 
21
, 
ALDH
+
 
191
, LGR5
+
 
192
, and CD44v6
+
 
193
 as phenotypes. In this study, I used the previously 
described and characterized “stem-like” markers, CD24, CD44, CD133 and CD166 to identify 
CCICs populations from three different colorectal cancer lines: SW480 (poorly differentiated), 
HT-29 (moderately differentiated) 
168
 and LS174T (well differentiated) 
169
 (Fig.1.3). FACS 
analysis showed that only within the HT-29 colon cancer cell line is it possible to identify a 
subpopulation characterized by the bright co-expression of all the four stemness markers 
evaluated, that likely represent the CCICs population. LS174T and SW480 colon cancer cell 
lines, do not show a bright intensity of CD133 and CD166 as HT-29 colon cancer cell line. 
This results can be explained by the differentiation potential of the cells, in fact low intensity 
of “stem-like” antigens expression on LS174T was expected considering that is a well 
differentiated colon cancer cell line 
169
. Although SW480 is a poor differentiated colon cancer 
cell line 
168
, the low expression of these markers can be explained considering that not all the 
cells with a low differentiation state are cancer stem cells 
7,23
; while a small population as the 
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one identified in HT-29 colon cancer cell line, with stemness potential and with bright 
intensity of CD24, CD44, CD133 and CD166 “stem-like” markers, can give rise to tumor 
initiation and formation 
6,8,21
. In particular, I focused my attention on the HT-29 
subpopulations expressing the CD24
Bright
/CD44
Bright
 and CD24
Dim
/CD44
Dim
 phenotype 
(Fig.2.3) that would represent, respectively, the CCICs, subpopulation and the more 
differentiated counterpart, as previously described by Yeung et al. 
33
. However, several 
questions remain open in the field of colorectal CSC identification. In fact, the consistency of 
CSC-associated markers needs to be further investigated, given that the CSC phenotype itself 
has been shown to be unstable. For example, CCICs enriched populations that are positive and 
negative for LGR5 can interconvert upon chemotherapy 
194
. Based on these findings, I further 
validated the stemness potential of the CD24
Bright
/CD44
Bright
 and CD24
Dim
/CD44
Dim
 isolated 
subpopulations. Neoplastic stem cells from neural and epithelial organs can be expanded as 
sphere-like cellular aggregates in serum-free medium containing EGF and FGF. Thus, colon 
undifferentiated cancer cells can be cultured and expanded in vitro as colon spheres in 
proliferative serum-free medium containing growth factors. This property is common to neural 
and epithelial stem and progenitor cells, which grow as spherical aggregates that in the 
presence of serum or extracellular matrix differentiate upon growth factor removal 
20,195-197
. To 
this end, I cultivated both the subpopulations of cells obtained upon fluorescence-activated 
cell sorting, in such a proliferative medium for undifferentiated cells. After 3 weeks of culture, 
I obtained colonospheres formed by aggregates of exponentially growing undifferentiated 
cells CD24
Bright
/CD44
Bright 
(CCICs) that were larger in terms of size and number compared to 
the ones obtained from the CD24
Dim
/CD44
Dim colon cancer cells (the more differentiated 
counterpart) (Fig. 3.3). This result can be explained considering that CD24 and CD44 are 
stem-like markers 
19,198
 therefore, cells that express these markers at higher intensity are 
supposed to be enriched in stemness properties, thus able to grow in such conditions. In this 
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contest, it has been shown that cytokines produced by tumor-associated cells can induce 
increased CSC self-renewal 
171,199,200
, therefore have a role in CSCs maintenance as external 
effectors. In fact, Todaro et al. demonstrated that the cytokines hepatocyte growth factor 
(HGF), osteopontin (OPN), and stromal-derived factor 1α (SDF-1), secreted from tumor 
associated cells, increase CD44v6 expression in CCICs by activating the Wnt/β-catenin 
signaling, which promotes migration and metastasis 
193. Thus, it is possible that the percentage 
of cells expressing CSC markers within a tumor, may vary depending on disease stage, 
considering that a more strict hierarchical organization has been proposed to be present in the 
early stages and more relaxed in advanced stages of the disease 
201
; also, this percentage may 
vary depending on the timing and type of therapy, and on a series of microenvironmental and 
individual factors that are predictably difficult to define. Therefore, in a dynamic scenario 
where CSCs may change in quantity and phenotype during tumor progression, the expression 
of CSC markers should be seen as a relative and contextual parameter rather than a general 
property of the tumor. Besides phenotypic markers, another way to identify CSCs is through 
their individual molecular and/or functional features. Interestingly, from the molecular side, 
the hallmark of colorectal CSCs has been shown to be a hyperactivated β-catenin pathway, 
which translates into the ability to generate serial tumors in vivo 
171
. Therefore, my first 
hypothesis was that the phenotypic differences between the CCICs and the more differentiated 
counterpart could be individually reflected at the molecular and functional level. To this 
purpose I performed RNA-Seq of CCICs (CD24
Bright
/CD44
Bright
), colonospheres and more 
differentiated counterpart (CD24
Dim
/CD44
Dim
), to explore pathways that could be eventually 
dys-regulated (Fig. 4.3). I analyzed the expression of genes defining differentiation or stem 
cell character in CCICs and in the more differentiated counterpart, and the results showed that 
genes involved in colonic mesenchymal cells differentiation, such as Mucin 2  (MUC2) 
172
 or 
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Keratin B20 (KB20/KRT80) 
202
 were down-regulated in CCICs demonstrating that this 
population is less differentiated compared to the CD24
Dim
/CD44
Dim
.  The increased expression 
of colon cancer stem cells markers, in particular CD24, CD44, CD166 and ALDH1A1, 
confirms the stemness potential of the cells. What was really interesting, was that members of 
the canonical Wnt-mediated signaling such as ASCL2, IGFBP2, LGR4, DKK1, MYCL1, 
FGFR2, SP5, MMP7 and the receptor EPHB3 were elevated in CCICs compared to the more 
differentiated counterpart (Fig. 5.3 and Fig. 6.3). The further overexpression of Wnt-signaling 
pathway genes in colonospheres confirmed by RNA-Seq (Fig. 7.3), corroborates the findings 
from Vermeulen et al 
171
. Moreover, the experiments that I performed on FBS-induced 
differentiation cells showed that the expression of Wnt-signaling target genes is drastically 
reduced upon differentiation, adding a further confirmation to the involvement of this 
signaling in colonospheres formation (Fig. 8.3). Self-renewal is a stem cell functional trait, 
which has been shown in some studies on colorectal cancer stem cells to be depend on some 
transcriptional regulators such as isopentenyl-diphosphate delta isomerase 1 (ID1) and -3 
(ID3)
203
, or BMI1 that has also been shown to be a key player of self-renewal in CCICs, as its 
inhibition results in stem cell loss and impairment of tumor growth 
204. Therefore, we may 
consider the idea of a new point of view where stemness arises from the continuous adaptation 
of cancer cell populations to microenvironmental signals. Increasing evidence suggests that, in 
both the normal and neoplastic intestine, stemness results from the incessant convergence of 
cell-intrinsic features (genetic mutations and epigenetic regulation), local signals (of a 
chemical, mechanical, and molecular nature), stochastic events, and population forces that 
continuously shape the stem cell pool 
205
. In particular, the epigenetic regulation of 
transcription is a complicated and comprehensive event, that can involve different players, and 
recent evidences revealed that long-noncoding RNAs can impersonate this role. Several 
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studies have shown that these lncRNAs can work as transcriptional activators or repressor, 
function as transcriptional guide, or act as scaffold for chromatin modification complex 
(reviewed in 
106
). To make a more direct point, it has been shown that the lncRNA ANRIL 
physically interacts with CBX7, member of PRC1 complex; this interaction induce formation 
of heterochromatin surrounding the INK4b-ARF-INK4a locus, leading to its repression. This 
mechanism facilitates the bypassing of senescence, endowing the prostate cancer cells 
stemness 
122,123
. Also, previous reports showed the involvement of lncRNAs in regulating cell 
stemness maintenance 
206,207
. Moreover, recent findings showed that lncRNAs play significant 
roles in regulating cellular development and differentiation, processes that are frequently 
deregulated in cancer 
208
.  The involvement of lncRNAs in colorectal cancer has been 
demonstrated from several groups, and in particular, Nissan et al. were the first showing that 
CRC-associated transcript 1 (CCAT1) is highly expressed in CRC but not in normal tissue 
209
, 
while Xiang et al. demonstrated that this lncRNA plays a role in MYC transcriptional 
regulation and promotes long-range chromatin looping 
182
. Interestingly, recent findings 
showed that, in cancer, the Wnt-pathway can be additionally regulated by lncRNAs 
181-183
. In 
this scenario, considering that HT-29 colon cancer cell line harbors an APC inactivating 
mutation (deletion at the carboxyl terminus at residue 1555) that gives rise to a truncated and 
inactive APC protein 
210-212
, inducing the cells to be insensitive to external stimulation by Wnt 
ligands, but sensitive to the constitutively activation of the Wnt-signaling within the cell 
213
, I 
conceived that new kinds of transcriptional regulator, not fully investigated yet, such as 
lncRNAs, could have a role during the colonospheres formation process, thus in CCICs 
maintenance by regulating the Wnt-signaling. For this reason, I performed a lncRNA profiler 
array analysis on CCICs and the more differentiated counterpart subpopulations from HT-29 
cell line, evaluating the differential expression of 90 different lncRNAs. The expression of 
several lncRNAs resulted to be increased in CCICs compared to the differentiated counterpart, 
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and in particular: HOXA6as, 7SK, NEAT1 (family), 7SL, lincRNA-p21, Tsix, Jpx, AntiPeg11, 
H19, Kcnq1ot1, NDM29, Hoxa11as, LUST, KRASP1, Prins, Malat1 and IGF2AS (family) 
(Table 1.3). According to the comprehensive lncRNA consortium database (lncRNAdb) 
(http://www.lncrnadb.org), most of the lncRNAs have been characterized to a degree at the 
functional level, except for HOXA6as, IGF2AS (family) and KRASP1 which role is still 
unknown. Among the upregulated lncRNAs, LUST was found overexpressed also in 
colonospheres (Fig. 7.3), suggesting a functional role played by this lncRNA during the 
colonospheres formation process. My data showed that only two lncRNAs were found 
increased in both, CD24
bright
/CD44
bright
 subpopulation and colonospheres, in particular, 
Kcnq1ot1 (KCNQ1 opposite transcript 1) and LUST (RBM5-AS1). Kcnq1ot1 has been widely 
characterized and has been demonstrated that this lncRNA has a role in the organization of a 
tissue/lineage-specific nuclear domain involved in epigenetic silencing of the Kcnq1 
imprinting control region. To further detail this concept, the expression profile, function and 
epigenetic alterations of this locus in colorectal cancer have been previously characterized 
116,214
. The functional role of the lncRNAs LUST (Luca-15 specific transcript/RBM5-AS1) has 
just been hypothesized. LUST is an antisense transcript of ~1.3kb that initiates within intron 6 
and terminates within intron 4 of the RBM5 gene. Sutherland et al. speculated that LUST binds 
and masks an unknown sense-strand regulatory sequence, common to two RBM5 different 
isoforms, preventing the premature termination of both mRNAs. In absence of LUST, the 
expression of this truncated isoform triggers apoptosis, therefore, conferring to LUST an 
antiapoptotic role 
149
. However, the molecular function of LUST remains still unclear and 
further investigations regarding its role and expression in colorectal cancer have never been 
pursued. The Wnt-signaling hyperactivation hallmark in colon cancer stem cells 
171
, and the 
regulating effect of this pathway in colorectal cancer, mediated by lncRNAs 
181-183
 made 
interesting to know whether a lncRNAs, in this case LUST, could act as a transcriptional 
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regulator of Wnt-signaling during colonospheres formation. Culture under FGF positive and 
EGF positive serum-free conditions has been used to expand stem-like spheroid cells from 
primary colorectal cancer cells (CRC) or from primary cell lines 
20,215,216
. To address the 
functional role of LUST on cancer stem cell maintenance, I performed in vitro colonospheres 
forming assays and analyzed by qRT-PCR the lncRNA and stemness markers mRNA levels. 
The expression of CD24 and CD44 resulted increased when HT-29 cells are grown in 
suspension, as confirmation of the cell stemness potential and the enrichment of CCICs within 
the colonospheres 
170
. Interestingly, the expression of LUST that was showed to be increased 
in my RNA-seq data obtained from colonospheres, is validated with this experiment. More 
directly, the increase of LUST is strongly significant after only 14 days in culture, when the 
stemness markers levels are not increased yet, and reaches a 10 fold change increase when 
cells are grown for 5 weeks in the same conditions (Fig. 9.3). This result suggests that LUST 
elevation could be an early event in the colonospheres formation process. Epithelial stem and 
progenitor cells can grow as spheroid aggregates and, upon growth factor removal and in 
presence of serum or extracellular matrix, can differentiate 
20,195-197
. To test this ability, and to 
investigate LUST behavior in such conditions, I induced colonospheres differentiation by 
adding fetal bovine serum (FBS) and by removing growth factor from the culture medium 
23
. 
As expected, when colonospheres differentiation is generated upon adding FBS, both mRNA 
and protein expression levels of the “stem-like” markers CD24 and CD44 is abrogated (Fig. 
10.3 and Fig. 11.3), confirming reduced stem-like potential. Interestingly, LUST expression 
strongly decreases upon induced differentiation, and this could be considered as a clear 
evidence of its involvement in stemness phenotype (Fig. 10.3). Recent studies have identified 
many lncRNA transcripts to be differentially expressed in pluripotent cells, both in ESCs and 
in iPSCs compared to fibroblasts or neuronal progenitors 
101,217-219
. In order to investigate 
LUST involvement in Wnt-signaling regulation I performed loss of function experiments using 
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lock nucleic acids (LNA) antisense probes (Fig. 12.3 A), demonstrating that LUST inhibition 
impairs the transcriptional activation of Wnt-signaling target genes (Fig. 13.3). In particular, 
the reduction of AXIN2, CCND1, MYC and of the stemness markers CD24 and CD44 mRNA 
levels, suggest the loss of stemness character; moreover the reduction of CCND1 and MYC 
gene product levels (Fig. 14.3) strongly indicate a reduction of cell proliferation (Fig.12.3 B) 
87,88
. Of interest, LUST knockdown reduces active β-catenin, confirming the decrease of Wnt-
signaling activation in absence of LUST (Fig. 13.3).  On the contrary, a dual luciferase assay 
was performed on LUST overexpressing cells, showing that the lncRNA alone as well as β-
catenin is able to activate the TCF-4 reporter mini-gene. Interestingly, co-transfection of 
pcDNA3-LUST and pcDNA3-β-catenin induces increase in luciferase activity (Fig. 15.3). 
These results demonstrate that the LUST transcript and β-catenin coordinately regulate Wnt/β-
catenin signaling. Furthermore, LUST overexpression in HT-29 colon cancer cell line, induces 
Wnt-signaling target genes and stemness markers transcription activation (Fig. 16.3), and the 
increase is also reflected at the protein level (Fig. 17.3), indicating that LUST actively 
regulates Wnt//β-catenin signaling. To identify the molecular basis by which the lncRNA 
regulates this pathway, I visualized LUST transcript subcellular localization to provide clues to 
its function. The nuclear/cytoplasmic RNA fractionation (Fig. 18.3) and the RNA 
fluorescence in situ hybridization (FISH) (Fig. 19.3) experiments revealed that LUST is a 
prominently nuclear lncRNA, to conceptualize a transcriptional or chromatin-based role. 
Previous studies reported that members of Wnt signaling such as β-catenin, can selectively 
bind RNA 
220,221
. Edwards et al., showed that the Armadillo repeats found within β-catenin are 
an evolutionary conserved structural order as a helical repeat protein family, that closely 
corresponds with Puf repeats of the RNA binding protein Pumilio. The Armadillo repeat 
structure reveals an extended, rainbow shaped molecule, with tandem helical repeats, that 
bears unexpected resemblance to Puf repeats in Pumilio as a distinct structure with strong 
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affinity to 3’-UTRs in mRNA 220. 
 
 
Figure 1.4: β-catenin and Pumilio protein structure 
β-catenin is a member of the highly conserved helical repeat protein family through the Armadillo 
repeats.  Two members of the family, β-catenin with arm repeats (left) is shown alongside Pumilio 
with Puf repeats (right). Shown below is a single repeat from each structure, aligned with functionally 
equivalent helices—H3 for Arm and Puf repeat structures. (Adapted from 220). 
 
This hypothesis, was further demonstrated by Kim et al. showing that β-catenin recognizes a 
specific RNA motif in the cyclooxygenase-2 mRNA 3’-UTR 221. Based on these findings I 
sought to analyze the hypothetical interaction of LUST with Wnt/β-catenin pathway members, 
by immuno-precipitating β-catenin trough RNA-Immuno-Precipitation (RIP). The strong 
enrichment of LUST binding to this protein, compared to the negative control (Fig. 20.3), 
opened new hypothesis of whether this lncRNA could bind to a mutated isoforms of the same 
protein. The CaCo-2 colon cancer cell line harbors both, APC and β-catenin mutations 187, 
making this colorectal cancer cell line suitable for my purposes. In attempt of identifying new 
binding partners of LUST, in case the missense mutation could have abrogated the binding site 
of the lncRNA for β-catenin, I performed cross-linking immuno-precipitation of β-catenin and 
the transcription factor TCF-4, known to induce transcriptional activation of Wnt-target genes 
59,60,222
. My results showed that: (i) LUST binds to β-catenin in CaCo-2 colorectal cancer cell 
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line (Fig. 21.3), therefore the missense mutation does not abrogate the binding site, instead, 
this mutation that lies within the third Armadillo repeat would increase the accessible surface 
area at that site 
223
, thus facilitating LUST binding to the protein; (ii) the increase of LUST 
binding is also reflected by RIP experiment performed in the same cell line (Fig. 22.3); (iii) 
lncRNA LUST binds to both, β-catenin and TCF-4, enforcing the hypothesis of a functional 
role in regulating Wnt-signaling (Fig. 21.3). Although these experiments add confirmations to 
my hypothesis, to further determine the regulatory role of LUST in Wnt/β-catenin signaling 
during colonospheres formation, the fallowing experiment was carried out, to examine 
whether overexpression of the lncRNA would eventually affect the process. The earlier 
colonospheres formation obtained (Fig. 23.3) confers the last and additional demonstration of 
the extremely important role of LUST in CICCs maintenance by regulating Wnt-signaling 
activation. The relevance of my thesis, therefore, results is in three distinct and significant 
areas of LUST-mediated processes in CCICs maintenance:  
 
(i) My work represents the first detailed characterization of LUST localization and role in the 
maintenance of CCICs self-renewal. 
(ii) I established a transcriptional activating regulatory model, whereby LUST function is 
essential for the transcriptional activation of the Wnt-signaling target genes (Fig. 2.4). 
(iii) I show a novel LUST function in regulating Wnt-signaling, essential to insure the CCICs 
maintenance. 
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                   Figure 2.4: LUST acts as trascritpional regulator of Wnt-signaling 
LUST regulates Wnt-signaling in CCICs through a coordinated physical interaction with β-catenin, 
inducing transcriptional activation of Wnt-signaling target genes, therefore promoting colon cancer 
initiating cells proliferation, self-renewal and phenotypic markers expression. 
 
To conclude, I demonstrated that the lncRNA LUST is critical for CCICs self-renewal, by 
transcriptional regulating the expression of Wnt-signaling target genes. Overexpression of the 
LUST transcript increases the expression levels of CCND1, active β-catenin and other key 
regulators of cell cycle and promotes cell proliferation, thereby triggering colonospheres 
formation. The direct connection between LUST and β-catenin in maintaining CCICs self-
renewal provides fundamental new insight into the transcriptional gene regulation network in 
cancer stem cell biology.  
Given the importance of β-catenin in tumorigenesis, it is plausible to consider that LUST 
overexpression is involved with cancer cell fate. Therefore, dissecting the molecular 
mechanisms that mediate this overexpression envision a use in predicting cancer risk, achieve 
an early diagnosis, or track the prognosis of tumor fate, and thereby, provide a scope of 
diagnostic or therapeutic possibilities. Currently, nucleic acid-based methods prevail in 
targeting RNA, either by regulating the level of lncRNAs in cancer cells as well as modifying 
their structures or mature sequences. Among them, RNA interference (RNAi) based 
  75 
techniques are arguably the most popular methods to inhibit lncRNAs in cancer cells. With the 
novel design of RNA through chemical modifications, the stability of these nucleic acid drugs 
is greatly improved 
224
, and combined with gene therapy technology, stable and persistent 
inhibition of aberrant lncRNAs can be resulted. Meanwhile, other established methods in 
inhibiting cancer-associated RNA, including antisense oligonucleotide (ASO), ribozyme and 
aptamer, are also effective to modulate lncRNAs, and they show unique features that can have 
advantages over siRNAs. On the other hand, the potential of the pharmacological modulation 
of β-catenin in cancer therapeutics may possibly provide an attractive option of targeting 
various aspects of the carcinogenic process i.e. initiation, progression and chemo-resistance in 
conjunction with the traditional chemotherapy. However, the long-term effects of the 
pharmacological manipulation of β-catenin remain still unclear and need to be taken in 
consideration, given that the overall regulation of this protein involves multiple signaling 
pathways. For this reason, the pharmacological modulation should be counterbalanced through 
the activation of compensatory signaling pathways. Furthermore, the possibility of adverse 
side effects of β-catenin inhibition cannot be ruled out at this juncture. To date, the use of 
various small molecule inhibitors of β-catenin targeting cancer have provided some 
encouraging results 
225
. To this purpose, more efforts can be directed towards evaluating the 
efficacy of the existing inhibitors against colon cancer initiating cells and chemoresistant 
cancers, as it is evident that microenvironmental regulation of the β-catenin activity plays a 
central role in the malignant transformation and induction of metastasis; thus, in this case, the 
development of multiple approaches is key to identify the most effective lncRNA-based 
therapy. Therefore, LUST would represent a perfect candidate for developing lead compounds 
directed against colon cancer initiating cells. In fact, targeting LUST, hence the Wnt/β-catenin 
signaling activity, could open new avenues for novel and tailor-made cancer therapeutic 
approaches.  
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